| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | MN-001 (tipelukast) hypertriglyceridemia, nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | |
Phase 2 topline data readout example | MN-001 (tipelukast) hypertriglyceridemia, nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System | |
Phase 2 topline data readout example | MN-001 (tipelukast) hypertriglyceridemia, nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM) | Phase 2 | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
MediciNova, Inc.$1.39
+0.01 (+0.72%)
C 59Pipeline Score Undervalued Pharma · Clinical
Market Cap
68.91 M
EPS
-0.24
P/E Ratio
-
Value Trade
34.04 K
SEC Financials
Q1 2026Dilution Risk
Revenue
186.98 K
R&D Expenses
1.20 M
Operating CF
-3.47 M
Total Assets
42.70 M
Total Liabilities
3.30 M
Equity
39.41 M
D/E Ratio
12,345
0.72 %
Week
-1.41 %
1 Month
-11.95 %
3 Month
-2.1 %
6 Month
-66.98 %
5 Year
-87.27 %
All Time
Cash Data
Cash Position
27.33 M
Monthly Burn
1.16 M
Runway
21.9 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
17.59 K
52 Week Range
1.17 - 1.96
% held by Insiders
5.12 %
% held by Institutions
8.73 %
Enterprise Value
41.75 M
Total Shares
49.23 M
Short %
0.51 %
Float Shares
40.32 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MediciNova, Inc.
888Total events
2Upcoming
205Tier-1 (high impact)
2005 – 2026Coverage
Upcoming catalysts 2
Event history 886
Q3 2026
◆Topline ReadoutMN-001Clinical Data
Top-line data expected for MN-001 Phase 2 trial
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
Jun 30, 2026
▲Last Patient Last VisitMN-001Trial
Last patient last visit completed in Phase 2 trial of MN-001 for hypertriglyceridemia and NAFLD with T2DM
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
Jun 30, 2026
▲Enrollment MilestoneMN-166Trial
100 patients enrolled in SEANOBI EAP for MN-166 in ALS (50% of planned enrollment)
amyotrophic lateral sclerosis (ALS)source ↗
Jun 30, 2026
▲Patent GrantedMN-166IP / Competition
Notice of Allowance for U.S. patent covering ibudilast in combination with anti-PD-1 antibody for glioblastoma
glioblastomasource ↗
Jun 8, 2026
▲Patent GrantedMN-166IP / Competition
Notice of Allowance for patent covering MN-166 in combination with anti-PD-1 for glioblastoma
glioblastomasource ↗
May 26, 2026
▲Last Patient Last VisitMN-001Trial
Last patient last visit completed in Phase 2 trial of MN-001 (tipelukast) for hypertriglyceridemia and NAFLD with T2DM
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
Q2 2026
◆Topline ReadoutMN-001Clinical Data
Top-line data expected by summer 2026
hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM)source ↗
Mar 22, 2026
◆Oral PresentationPresentation
MediciNova to participate at 38th Annual ROTH Conference with one-on-one meetings
Mar 2026
Mar 2026
▲PublicationMN-166Presentation
Publication of MIF-CD74 study in Cancer Research
brain metastasissource ↗
2026
◆Topline ReadoutMN-166Clinical Data
Topline data for COMBAT ALS Phase 2b/3 Registration trial of MN-166
amyotrophic lateral sclerosis (ALS)source ↗
Jan 2026
▲Enrollment MilestoneMN-166Trial
100 patients enrolled in SEANOBI EAP (50% of planned 200 enrollment)
amyotrophic lateral sclerosis (ALS)source ↗
Drug Pipeline Intelligence
C59
Pipeline Score $298M
Pipeline ValueUndervalued
Valuation Signal5
Drugs Scored4.3x
rNPV / MCap Top 86%
Micro Cap (rank 129 of 911)
Percentile RankMediciNova, Inc. carries a moderate pipeline score (59/100), with $5.9B risk-adjusted pipeline value, led by MN-001 in Diabetes Mellitus, Type 2 (Phase 2), across $167B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MN-001 Small molecule | Diabetes Mellitus, Type 2 | Phase 2 | NCT05464784 | 23% | $4.7B | ACTIVE NOT_RECRUITING | 40 | STALLED | C (56) | Dec 31, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
MN-001 | hypertriglyceridemia, Type 2 DM and NAFLD | Phase 2 | 2025-10-30 | improved serum lipid profiles in patients with Non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with particularly notable effects in patients with type 2 diabetes (DM) Read More | MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication Read More | |
MN-001 | hypertriglyceridemia, Type 2 DM and NAFLD | Phase 2 | 2025-10-30 | improved serum lipid profiles in patients with Non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with particularly notable effects in patients with type 2 diabetes (DM) Read More | MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication Read More | |
MN-001 | hypertriglyceridemia, Type 2 DM and NAFLD | Phase 2 | 2025-10-30 | improved serum lipid profiles in patients with Non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, with particularly notable effects in patients with type 2 diabetes (DM) Read More | MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MNOV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MNOV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MNOVMediciNova CEO Provides Shareholder Update
MediciNova, Inc. has provided a corporate update highlighting significant progress in its clinical trials, particularly the completion of the last patient visit in the Phase 2 trial for MN-001. The company anticipates initial data readout in Q3 2026. Additionally, MediciNova has strengthened its intellectual property portfolio and increased its equity research coverage, signaling growing investor interest.
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
MediciNova, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the use of MN-166 in combination with anti-PD-1 immune checkpoint inhibitors for glioblastoma treatment. This patent is expected to enhance the company's intellectual property position and support ongoing evaluation of MN-166 in oncology. The patent claims include various treatment parameters, indicating a strategic approach to addressing glioblastoma.
Read more →MNOVMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova, Inc. has announced the completion of the last patient last visit in its Phase 2 clinical trial, MN-001-NATG-202, for MN-001 (tipelukast). This trial evaluates the drug's effectiveness in treating hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes. The study's co-primary endpoints focus on liver fat content and fasting serum triglycerides, with top-line data anticipated in Q3 2026.
Read more →MNOVNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
MediciNova, Inc. announced a study revealing macrophage migration inhibitory factor (MIF) as a key target in brain metastasis. The research showed that ibudilast can inhibit MIF-CD74 signaling, potentially reversing immune reprogramming and reducing metastatic progression. The findings support a biomarker-guided clinical strategy for treating patients with brain metastases, with plans for collaboration on future clinical studies.
Read more →MNOV▲ +7.4%on this news
MediciNova to Participate at the 38th Annual ROTH Conference
MediciNova, Inc. will participate in the 38th Annual ROTH Conference from March 22-24, 2026. CEO Yuichi Iwaki and CBO David Crean will engage with investors through meetings to discuss company updates. MediciNova is advancing its clinical-stage therapies, including MN-166 and MN-001, targeting various diseases.
Read more →MNOVMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova has announced the enrollment of 100 patients in the SEANOBI Expanded-Access Program, which aims to evaluate MN-166 (ibudilast) in ALS patients. This milestone represents 50% of the planned enrollment of 200 patients across 12 sites in the U.S. The program is supported by a $22 million NIH grant and aims to provide treatment access while collecting valuable clinical data. The company also continues its COMBAT-ALS study, which is expected to yield top-line results by the end of 2026.
Read more →MNOVMediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
MediciNova, Inc. has announced the successful completion of patient enrollment for its Phase 2 OXTOX study, evaluating MN-166 (ibudilast) in preventing chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients. A total of 100 patients were randomized into two treatment arms across 11 clinical sites in Australia. Participants will continue treatment until disease progression or unacceptable side effects, with preliminary data expected in 2026. The study is part of broader late-stage clinical development of MN-166 for various serious conditions, including neurodegenerative diseases.
Read more →MNOVMediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
MediciNova has provided an update on its Phase 2b/3 clinical trial of MN-166 (ibudilast) for ALS, presented at the 36th International Symposium on ALS/MND. Despite challenges like slow enrollment during the COVID-19 pandemic, the company achieved its randomization goal and anticipates top-line data by the end of 2026. MN-166 has received Orphan Drug and Fast Track designations from the FDA.
Read more →MNOVMediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
MediciNova, Inc. has announced the appointment of Dr. Christopher D. Breder, MD, PhD, as its new Clinical and Regulatory Advisor. Dr. Breder is recognized for his extensive experience at the FDA and in the pharmaceutical industry, particularly in neurological therapies. His expertise will guide MediciNova's drug development programs and aid in the formation of a Scientific Advisory Board. The company is focused on advancing therapies for neurodegenerative diseases, with its lead asset, MN-166, currently in Phase 3 trials for ALS and DCM.
Read more →MNOVMediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
MediciNova, Inc. has been awarded the 'Contract Research and Development Innovation Award' at the Fifth Annual BioTech Breakthrough Awards for its work on MN-166, a drug candidate for ALS. The award underscores the company's commitment to developing therapies for neurological diseases. MediciNova is currently conducting a Phase 2/3 trial for MN-166, aiming to address significant unmet medical needs in ALS treatment.
Read more →MNOV▼ -5.3%on this newsshared move
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova, Inc. has completed patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, which evaluates MN-001 (Tipelukast) for treating hypertriglyceridemia and non-alcoholic fatty liver disease associated with Type 2 diabetes. The trial is randomized, double-blind, and placebo-controlled, with top-line data expected in summer 2026. MN-001 is noted for its anti-inflammatory and anti-fibrotic properties.
Read more →MNOV▲ +39.5%on this newsshared move
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
MediciNova, Inc. announced the publication of a study in the Journal of Atherosclerosis and Thrombosis, highlighting the potential of MN-002, a metabolite of MN-001, in enhancing cholesterol efflux. This research indicates a novel therapeutic strategy for atherosclerosis. The company is also advancing clinical trials for MN-001 in various metabolic diseases.
Read more →MNOVMediciNova to Present at the LD Micro Main Event XIX Investor Conference
MediciNova, Inc. will present a corporate overview at the LD Micro Main Event XIX Investor Conference from October 19 to 22, 2025. CEO Yuichi Iwaki and CBO David Crean will lead the presentation, which will be available via live webcast. The company is developing a robust pipeline of therapies for various diseases, including ALS and MS.
Read more →MNOVMediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
MediciNova, Inc. has announced the completion of patient enrollment in its Phase 2b/3 clinical trial, COMBAT-ALS, for MN-166 (ibudilast) targeting ALS treatment. A total of 234 patients were enrolled across multiple sites in the U.S. and Canada. The trial aims to evaluate the drug's efficacy and safety, with top-line data expected by the end of 2026.
Read more →MNOVMediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
MediciNova, Inc. announced that an abstract for the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in ALS patients will be presented at the 36th International Symposium on ALS/MND. The presentation will cover trial updates and baseline characteristics, showcasing the company's ongoing commitment to addressing neurodegenerative diseases. The event is scheduled for December 5-7, 2025, in San Diego, CA.
Read more →MNOVMediciNova Provides Shareholder Update on Key Developments
MediciNova, Inc. has provided a shareholder update highlighting key developments, including the signing of a $30 million Standby Equity Purchase Agreement and successful enrollment in its COMBAT-ALS Phase 2b/3 trial for MN-166. The company is also advancing other trials, including a Phase 2 trial for MN-001. CEO Dr. Yuichi Iwaki expressed optimism about the company's progress and funding strategies.
Read more →MNOVMediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MediciNova, Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The presentation will be led by CEO Yuichi Iwaki and CBO David H. Crean. MediciNova is developing a robust pipeline of therapies for various diseases, including ALS and progressive MS. The company also encourages investor engagement through one-on-one meetings during the event.
Read more →MNOVMediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial
MediciNova, Inc. has successfully completed participant enrollment for its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast), aimed at treating Amyotrophic Lateral Sclerosis (ALS). This milestone reflects effective collaboration among various stakeholders, including clinical sites and patient communities. The trial's progression brings the company closer to understanding MN-166's potential impact on ALS patients.
Read more →MNOV▲ +7.9%on this news
MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million
MediciNova, Inc. has signed a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors for up to $30 million over 36 months. This agreement allows MediciNova to sell its common stock at a discount, providing additional capital flexibility to support its R&D initiatives. The company aims to advance its clinical programs while managing associated risks.
Read more →MNOVMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
MediciNova, Inc. has provided updates on its ongoing clinical trials for compounds MN-166 and MN-001, indicating significant progress in enrolling participants. The company is close to completing the randomization of patients in its Phase 2/3 COMBAT-ALS trial. Additionally, final arrangements are being made for the last two subjects in a Phase 2 trial for dyslipidemia and fatty liver disease. The CEO highlighted the positive reception of MN-166 in the ALS community and the support received for the Expanded Access Program.
Read more →MNOVMediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
MediciNova, Inc. announced its participation in the Inaugural DBC Conference on May 14, 2025, in New York City, where CEO Yuichi Iwaki and CBO David H. Crean will discuss the company's leading programs in neurological and metabologic disorders. This conference aims to facilitate connections between public and private executives and institutional investors. The company's strategy focuses on developing its pipeline therapies, despite facing significant challenges in funding, clinical trials, and regulatory approval.
Read more →MNOVMediciNova Corporate Presentation March 2025 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provis
MediciNova presented forward-looking statements regarding its clinical trials and product candidates, MN-166 and MN-001, highlighting potential treatments for various diseases. The company noted the inherent risks and uncertainties in clinical trial execution, financial stability, and future market expectations. Positive results from earlier trials suggest promising efficacy, while potential challenges remain concerning funding and regulatory approvals. MediciNova continues to collaborate with academic institutions, facilitating a capital-efficient development model.
Read more →MNOVMediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
MediciNova, Inc. announced an update on its COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) for ALS, presenting interim analysis results at the 35th International Symposium on ALS/MND. As of November 15, 2024, 217 participants were enrolled, with positive correlations identified in various assessment scores at 6 and 12 months. The Data Safety Monitoring Board supports the continuation of the trial, which is expected to conclude patient assignments by June 2025, with trial results anticipated in 2026. An Expanded Access Program is also in place to allow ongoing treatment for patients following the open-label phase.
Read more →MNOV▲ +5.6%on this news· ran to +18% by day 3
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
MediciNova, Inc. has issued a corporate update from CEO Yuichi Iwaki, highlighting a strategic partnership with NIH to fund a trial for MN166, addressing ALS. The company maintains a strong cash position and focuses on targeted trials to maximize shareholder value while minimizing costs. Additional projects include a trial for Long COVID funded by Health Canada, further diversifying its pipeline with innovative trials. MediciNova aims to enhance communication with shareholders during its dual listings on NASDAQ and the Tokyo Stock Exchange.
Read more →MNOV▼ -8.8%on this newsshared move
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering MN-001, which focuses on reducing triglyceride synthesis in the liver. This patent is applicable for subjects with insulin resistance and diabetes, showcasing the potential for innovative treatments in metabolic disorders. Once issued, the patent will protect this method until at least May 2042. The company's Chief Medical Officer highlighted the significance of this development in advancing their treatment options.
Read more →MNOVMediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MediciNova, Inc. has announced the successful settlement of the Sanofi-Novartis litigation, entitling the company to monetary damages. This development is viewed as a validation of MediciNova's intellectual property and an opportunity for additional funding to support clinical development programs. The company's CEO emphasized the significance of this resolution for advancing their late-stage pipeline aimed at treating inflammatory and neurodegenerative diseases. Further details on the monetary damages are expected to be released in the future.
Read more →MNOVMediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
MediciNova, Inc. recently presented an update on its Phase 2/3 clinical trial of MN-166 (ibudilast) for ALS at the 2024 NEALS Meeting. The presentation, led by Dr. Björn Oskarsson, provided insights on trial design and enrollment progress. The trial aims to assess the efficacy of MN-166 in treating ALS, with additional NIH funding supporting an Expanded Access Protocol for patients. The company is in late-stage development for several neurodegenerative diseases, with a focus on MN-166's potential benefits.
Read more →MNOV▲ +9.9%on this news
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
MediciNova, Inc. has announced a $22 million grant from the NIH for an Expanded Access Protocol to evaluate MN-166 (ibudilast) in ALS patients. This protocol will provide the investigational drug to individuals not eligible for the COMBAT-ALS trial, assessing its efficacy through biomarker evaluation. The program is part of efforts backed by the ACT for ALS legislation aimed at improving access to experimental therapies for serious conditions. MediciNova expresses gratitude for the support from NIH and acknowledges the importance of this initiative for ALS patients.
Read more →MNOV▼ -9%on this news
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
MediciNova, Inc. announced that an abstract on the clinical trial of MN-166 (ibudilast) in the treatment of ALS has been accepted for a poster presentation at the upcoming 35th International Symposium on ALS/MND. This event is scheduled to take place in Montreal, Canada, from December 6-8, 2024, and will feature an interim analysis of the COMBAT-ALS trial. The lead investigator, Dr. Björn Oskarsson, will present the findings, highlighting the progress of MN-166 in late-stage development. This development reflects advancements in treatments for neurodegenerative diseases.
Read more →MNOV▲ +10%on this news· ran to +40% by day 3
MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
MediciNova, Inc. announced the acceptance of an abstract regarding its phase 2b/3 clinical trial for MN-166 (ibudilast) in ALS, to be presented at the 2024 Annual NEALS Meeting. This presentation will be conducted by lead Principal Investigator Dr. Björn Oskarsson. MN-166 is currently in late-stage development for ALS and other neurodegenerative diseases, but the company acknowledges potential risks in funding and regulatory approval for ongoing trials.
Read more →MNOVMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
MediciNova, Inc. announced the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent concerning MN-166 (ibudilast) in treating post-COVID conditions. The patent covers various methods of administration and associated therapeutic uses, extending potential treatment options. Furthermore, the company plans to apply for a New Drug Application based on upcoming clinical trial results, indicating ongoing commitment to addressing health challenges arising from COVID-19.
Read more →MNOVMediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
MediciNova, Inc. has announced that Chief Business Officer David H. Crean, Ph.D., will now lead the company's investor engagement and public relations efforts. This initiative aims to enhance communications with stakeholders regarding the company's strategic direction and ongoing projects. Crean's appointment is part of a broader strategy to increase transparency and clarity, especially after previous communications have been viewed as conservative. The company believes engaging more openly with investors will help convey its unique value proposition in addressing neurodegenerative diseases and other conditions.
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
MediciNova, Inc. has announced the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent covering MN-166 (ibudilast) aimed at preventing metastasis in several solid cancers. This patent extends the existing intellectual property for MN-166 and is key for its future application in combination therapies. The patent allows for a range of dosing and administration methods, and it is expected to boost the potential for MN-166 in the oncology space. Furthermore, MN-166 is also involved in late-stage clinical trials for neurological conditions, underscoring its versatility and importance to the company.
Read more →MNOV▲ +8.1%on this newsshared move
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
MediciNova presented data from a Phase 1b/2a clinical trial of MN-166 (ibudilast) in glioblastoma patients at the ASCO Annual Meeting 2024. The trial showed that the combination of MN-166 and temozolomide (TMZ) was safe and well tolerated, with a 6-month progression-free survival rate notably higher in recurrent GBM patients compared to historical controls. However, overall survival rates did not exceed those of prior studies. The findings suggest potential benefits when MN-166 is combined with existing immunotherapy strategies.
Read more →MNOVMediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MediciNova, Inc. announced two poster presentations at the 92nd European Atherosclerosis Society Congress 2024 regarding MN-001 and its metabolite MN-002. The presentations highlighted positive Phase 2 trial results for MN-001 in treating non-alcoholic fatty liver disease and demonstrated MN-002's effects on cholesterol efflux capacity. Although three serious adverse events were recorded during the trial, they were deemed unlikely related to the treatment. The data suggests promising outcomes for MN-001 and its role in lipid metabolism, further supported by collaboration with Juntendo University.
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
MediciNova, Inc. announced the receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a new patent on its compound MN-166 (ibudilast). This patent specifically covers the use of MN-166 in preventing metastasis in eye cancer, including uveal melanoma, and is anticipated to be valid until at least July 2042. The Company’s Chief Medical Officer highlighted previous research indicating the compound's effectiveness in inhibiting cancer spread and improving immune response within the tumor microenvironment. The issuance of this patent is expected to enhance the value of MN-166 within the oncology field.
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
MediciNova, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering MN-166 (ibudilast) for chlorine-induced acute respiratory distress syndrome (ARDS). This patent, which is expected to expire no earlier than January 2042, includes claims for various administration methods and dosing regimens. The Chief Medical Officer expressed optimism about the patent's potential to increase MN-166's value, supported by recent nonclinical findings suggesting improved pulmonary function and survival rates in tests involving chlorine-induced lung damage.
Read more →MNOVMediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
MediciNova, Inc. has announced the receipt of an issue notification from the U.S. Patent and Trademark Office for a new patent focusing on extended-release formulations of MN-166 (ibudilast). This patent is anticipated to last until at least September 2040 and covers various doses of the formulation. Kazuko Matsuda, the Chief Medical Officer, expressed optimism that the new formulation may enhance patient compliance and help mitigate side effects. MN-166 is currently in late-stage clinical development for several neurodegenerative diseases, along with potential applications in other medical conditions.
Read more →MNOVMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
MediciNova, Inc. announced that an abstract regarding the results of a clinical trial for MN-166 (ibudilast) in glioblastoma has been accepted for oral presentation at the 2024 ASCO Annual Meeting. The presentation will occur on June 2, 2024, led by Dr. Gilbert Youssef from Harvard Medical School. This highlights the company's progress in developing treatments for glioblastoma and other serious diseases, showcasing the potential of MN-166 as a therapeutic agent in oncology and neurology.
Read more →MNOVMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
MediciNova, Inc. has announced that it received a Notice of Allowance from the Japan Patent Office for a new patent regarding MN-166 (ibudilast), which is aimed at treating macular injury associated with progressive multiple sclerosis. This patent is expected to extend its commercial value until at least October 2039. The allowed claims encompass various forms of administration and dosing regimens for MN-166. The company's Chief Medical Officer expressed optimism about the patent's potential to increase the drug's value, particularly based on encouraging clinical trial results.
Read more →MNOVMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
MediciNova, Inc. announced that two abstracts related to MN-001 (tipelukast) and MN-002 have been accepted for presentation at the 92nd European Atherosclerosis Society Congress. The abstracts cover the ongoing clinical trial regarding MN-001's efficacy in treating non-alcoholic fatty liver disease and the mechanism of action of MN-002 in cholesterol metabolism. Chief Medical Officer Kazuko Matsuda highlighted the significance of these presentations, which underscore the company's dedication to addressing metabolic syndrome and related conditions through innovative research.
Read more →MNOVMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
MediciNova, Inc. announced promising results from a nonclinical study of MN-166 (ibudilast) for chlorine gas-induced acute lung injury at the Society of Toxicology Annual Meeting. The study demonstrated that a multi-dose treatment of 20 mg of MN-166 significantly improved pulmonary function and survival rates compared to control groups. All tested subjects in the high-dose treatment group survived the 48-hour observation post-treatment, with improvements noted in key pulmonary metrics such as the PaO2/FiO2 ratio. This research aligns with prior studies indicating the potential of MN-166 in treating acute lung injuries.
Read more →MNOVMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
MediciNova, Inc. announced the receipt of a Notice of Grant for a new patent from the Chinese Patent Office covering MN-166 (ibudilast) for treating macular injury related to progressive multiple sclerosis. This patent's allowed claims include various administration forms and dosing regimens, with an expiry expected no earlier than April 2040. The Chief Medical Officer highlighted prior success in demonstrating MN-166's potential in treating neurodegenerative diseases and positive outcomes from clinical trials. This development is consistent with similar patents granted in the U.S. and Europe, potentially enhancing the value of MN-166.
Read more →MNOVMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
MediciNova, Inc. announced that an abstract detailing the safety and pharmacological activity of MN-166 (ibudilast) in chlorine gas-induced lung injury has been accepted for poster presentation at the Society of Toxicology's 63rd Annual Meeting. The study, conducted in a relevant ovine model, will be presented by Dr. Perenlei Enkhbaatar. MN-166 is actively being developed for several conditions including ALS and Long COVID. This presentation is part of MediciNova's ongoing commitment to innovative research in respiratory toxicology.
Read more →MNOVMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
MediciNova, Inc. announced the receipt of a Notice of Decision to Grant from the European Patent Office for a new patent related to MN-166 (ibudilast) combined with interferon-beta for treating progressive multiple sclerosis (MS). This patent is expected to expire no earlier than October 2039 and covers various methods of administration. The Chief Medical Officer highlighted potential synergistic effects of the combination, indicating lowered risks of disability progression. MediciNova is furthering its development pipeline with ongoing trials in multiple indications.
Read more →MNOV▲ +15.7%on this news
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
MediciNova, Inc. presented promising Phase 2 clinical trial results for MN-166 (ibudilast) in glioblastoma at the Society for Neuro-Oncology Annual Meeting. The trial demonstrated that the combination treatment of MN-166 and temozolomide was safe and well-tolerated, with improved progression-free survival rates in recurrent glioblastoma patients. Preclinical studies also indicated enhanced survival outcomes with the combination therapy compared to individual treatments. The company expressed excitement about the findings and plans to evaluate MN-166 in future trials.
Read more →MNOVMediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
MediciNova, Inc. has announced that its collaborator, Genzyme Corporation, has treated the first patient in a clinical trial for SAR444836, a gene therapy aimed at treating phenylketonuria (PKU). This product relies on adeno-associated virus (AAV) vector technology and is part of an assignment agreement between MediciNova and Genzyme. The company continues to develop a robust portfolio of therapies for various diseases, highlighting its commitment to innovative treatments.
Read more →MNOVMediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
MediciNova, Inc. has announced the receipt of a Notice of Allowance for a new patent from the Canadian Intellectual Property Office, which covers the use of its drug MN-166 (ibudilast) in combination with riluzole for the treatment of amyotrophic lateral sclerosis (ALS). This patent, expected to be issued soon, will extend protection until at least November 2035. The claims encompass various dosage forms, including tablets and capsules, aimed at slowing ALS progression. MediciNova is currently conducting Phase 3 clinical trials in North America for this combination therapy.
Read more →MNOVMediciNova Receives Gene Therapy Milestone Payment
MediciNova, Inc. has announced the receipt of a $1 million milestone payment from Genzyme Corporation following the successful achievement of a clinical development milestone related to its gene therapy product. The company is actively developing multiple clinical programs, particularly with its leading asset MN-166, which is in advanced stages for conditions such as amyotrophic lateral sclerosis and progressive multiple sclerosis. This milestone reflects MediciNova's progress in its gene therapy efforts and its commitment to addressing serious medical conditions.
Read more →MNOVMediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova, Inc. announced positive results from nonclinical studies under a BARDA contract, investigating MN-166 (ibudilast) as a countermeasure for chlorine gas-induced lung injury. The drug exhibited significant improvements in pulmonary function without safety concerns. In a multi-dose study, a high dose of MN-166 led to a substantial enhancement in the PaO2/FiO2 ratio, indicating a recovery from acute respiratory distress syndrome (ARDS). The company aims to meet with the FDA to advance the development of this medical countermeasure, highlighting a significant unmet medical need in addressing chlorine gas exposure.
Read more →MNOV▼ -6.6%on this news
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
MediciNova, Inc. has announced that an abstract regarding MN-166 (ibudilast) in glioblastoma has been accepted for presentation at the Society for Neuro-Oncology meeting in November 2023. The poster will detail research on how pretreatment tumor tissue evaluation can predict treatment response to MN-166 combined with Temozolomide. MN-166 is in late-stage development for several indications, including glioblastoma. The poster will be presented by a prominent researcher affiliated with Cleveland Clinic and Case Western Reserve University.
Read more →MNOV▲ +6.9%on this newsshared move
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
MediciNova, Inc. has announced it received a Notice of Intention to Grant from the European Patent Office for MN-166 (ibudilast), aimed at treating macular injury linked with progressive multiple sclerosis. The patent, which is expected to expire in October 2039, suggests a broadened therapeutic potential for MN-166 in ophthalmic conditions. Past positive clinical data has further supported this development, indicating MN-166's efficacy in reducing retinal tissue loss. The CMO expressed optimism that this new patent could significantly enhance the value of MN-166 in the market.
Read more →MNOVMediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
MediciNova, Inc. has announced the receipt of a new patent from the European Patent Office for MN-001 (tipelukast), intended for the treatment of scleroderma and systemic sclerosis. This patent, which is valid until at least June 2035, covers a range of administration methods and dosages. The development is supported by positive results from recent animal studies. In addition, MN-001 has received Fast Track status from the FDA and is involved in multiple clinical trials for inflammatory diseases.
Read more →MNOVMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
MediciNova, Inc. has announced the receipt of a Notice of Intention to Grant from the European Patent Office for a patent covering MN-001 and MN-002, aimed at treating advanced nonalcoholic steatohepatitis (NASH). This patent is expected to expire no earlier than May 2035 and includes multiple claims related to the treatment of advanced NASH. The company previously reported positive Phase 2 clinical trial results for MN-001 in patients with NASH and hypertriglyceridemia and has also received Fast Track designation from the U.S. FDA for MN-001. Overall, this development could potentially enhance the value and prospects of MN-001 in the biopharmaceutical market.
Read more →MNOVMediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
MediciNova, Inc. recently presented results from its Phase 2b trial of MN-166 (ibudilast) for alcohol use disorder (AUD) at the RSA Scientific Meeting. The trial enrolled 102 treatment-seeking participants and aimed to reduce heavy drinking, but MN-166 did not demonstrate superiority to placebo in any primary or secondary endpoints. The results showcased a notable placebo effect, undermining the efficacy of the treatment. The company plans to conduct further analyses to explore future directions for MN-166.
Read more →MNOVMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
MediciNova, Inc. announced that it has received a Notice of Intention to Grant from the European Patent Office for a new patent related to MN-166 (ibudilast) targeting microorganism infections. Once granted, the patent will provide broad claims for its use as a monotherapy in various infections and is expected to expire no earlier than February 2039. The patent is anticipated to significantly enhance the potential value of MN-166, which has already shown positive results in treating severe COVID-19 pneumonia. The company continues to develop MN-166 for various indications including neurodegenerative diseases.
Read more →MNOVMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
MediciNova, Inc. has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering MN-001 in the treatment of advanced NASH. The patent will protect the drug's development and application until at least May 2035. MN-001 has shown positive Phase 2 clinical trial results, particularly for NASH patients with hypertriglyceridemia. The FDA has also granted Fast Track designation for MN-001, indicating its potential in clinical development for advanced liver conditions.
Read more →MNOVMediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
MediciNova, Inc. has announced an extension to its contract with BARDA, enabling further development of MN-166 (ibudilast) as a medical countermeasure for chlorine gas-induced lung injuries. This modification extends the project until May 31, 2023, supporting its potential to treat conditions like ARDS and ALI. MN-166 is already in late-stage clinical development for several neurodegenerative diseases and is part of a robust portfolio of therapies aimed at inflammatory and fibrotic diseases. The announcement underscores the continued push for innovative treatments within a favorable funding environment.
Read more →MNOVMediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
MediciNova, Inc. announced new findings related to MN-166 (ibudilast) in glioblastoma, presented by Dr. Justin Lathia at the 20th Annual World Congress of SBMT. The study highlighted potential predictors of treatment response based on tumor tissue analysis from clinical trial participants. Results suggest that lower CD3+ T cell percentages correlate with better treatment outcomes. The company emphasizes the significance of these findings amid the challenging prognosis associated with glioblastoma.
Read more →MNOVMediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
MediciNova, Inc. has received authorization from Health Canada to begin a multi-arm Phase 2/3 clinical trial, named RECLAIM, to evaluate MN-166 (ibudilast) and other therapies for Long COVID. This trial aims to address the lingering symptoms associated with COVID-19, which affect a significant percentage of recovered patients. The study will randomly assign participants to receive either MN-166, pentoxifylline, or placebo, and will track their progress over six months. MediciNova's initiative highlights the company’s commitment to addressing critical healthcare challenges in the ongoing aftermath of the pandemic.
Read more →MNOVMediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
MediciNova, Inc. has announced the completion of enrollment for its Phase 2b clinical trial assessing MN-166 (ibudilast) as a treatment for Alcohol Use Disorder (AUD). The trial, designed to evaluate the drug's efficacy in reducing alcohol consumption among treatment-seeking individuals, involved 102 participants taking MN-166 or placebo over 12 weeks. The study, funded by the National Institute on Alcohol Abuse and Alcoholism, aims to provide insights into MN-166's effectiveness in managing AUD, with topline results anticipated soon.
Read more →MNOVMediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
MediciNova, Inc. has completed enrollment in its Phase 2 clinical trial for MN-166 (ibudilast) targeting recurrent and newly diagnosed glioblastoma, conducted at Dana-Farber Cancer Institute. The trial consists of a dose-escalation phase followed by an efficacy evaluation phase involving the combination of MN-166 and temozolomide (TMZ). Preliminary findings from Part 1 are to be presented at the upcoming 20th Annual World Congress of SBMT, with further results expected after the meeting. The study aims to potentially identify predictors for treatment response in glioblastoma patients.
Read more →MNOVMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
MediciNova, Inc. announced the receipt of a Notice of Allowance from the Canadian Intellectual Property Office for a patent that covers its compounds MN-001 and MN-002, which are intended for treating scleroderma and systemic sclerosis. This allowed patent application is based on favorable results from previous studies and is expected to bolster the potential market value of MN-001. The patent will secure exclusive rights until at least June 2035, further supporting the company's therapeutic developments in chronic inflammatory diseases. MN-001 has demonstrated effectiveness in various clinical trials and has received regulatory recognitions such as Fast Track status.
Read more →MNOVMediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
MediciNova, Inc. announced the completion of a Phase I clinical trial for its intravenous formulation of MN-166 (ibudilast), which showed a favorable safety profile and was well tolerated among healthy volunteers. The new formulation is intended for treating severe inflammatory conditions, potentially benefiting hospitalized patients who cannot take oral medication. The company plans to meet with the U.S. FDA to discuss further development pathways toward approval. MN-166 is already being evaluated for various conditions, including ALS and glioblastoma.
Read more →MNOVMediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
LA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuk
Read more →MNOVMediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
LA JOLLA, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a secondary analysi
Read more →MNOVMediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will be conducting one-on-one virtual
Read more →MNOVMediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received an Issue Notification fr
Read more →MNOVMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
LA JOLLA, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from th
Read more →MNOVMediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
LA JOLLA, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to participate in RECLAIM (Recov
Read more →MNOVMediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
LA JOLLA, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Serum Lip
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
LA JOLLA, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
LA JOLLA, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a Phase 2 clinical trial to
Read more →MNOVMediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
LA JOLLA, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a first-in-human clinical s
Read more →MNOVMediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
LA JOLLA, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced a modification to its contract with the Biome
Read more →MNOVMediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive researc
Read more →MNOV▲ +8.9%on this news
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
LA JOLLA, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive top-line results from MediciNova’s P
Read more →MNOVMediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
LA JOLLA, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chi
Read more →MNOVMediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
LA JOLLA, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced data demonstrating that MN-166 (ibudilast) pr
Read more →MNOVMediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
LA JOLLA, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 clinical trial of MN-166 (i
Read more →MNOVMediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
LA JOLLA, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the U.S. Food and Drug Administration (
Read more →MNOVMediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
LA JOLLA, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a secondary analysis of a Phase 2 clinic
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea
LA JOLLA, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fr
Read more →MNOVMediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest
LA JOLLA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President
Read more →MNOVMediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
LA JOLLA, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MN-166 (ibudilast) was discussed as a pot
Read more →MNOVMediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs
LA JOLLA, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced MN-166 (ibudilast) was discussed as one of the
Read more →MNOVMediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea
LA JOLLA, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a new patent from the Kor
Read more →MNOV▲ +6.6%on this newsshared move
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada
LA JOLLA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOV▼ -5.1%on this newsshared move
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
LA JOLLA, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS
LA JOLLA, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND
LA JOLLA, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific A
Read more →MNOVMediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology
LA JOLLA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justi
Read more →MNOVMediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
LA JOLLA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator Masats
Read more →MNOVMediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting
LA JOLLA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Grazia Ambrosini, PhD, an associate resea
Read more →MNOVMediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology
LA JOLLA, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Dr. Justin Lat
Read more →MNOVMediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)
LA JOLLA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “MN-001 (tipelukast) redu
Read more →MNOVMediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the virtu
Read more →MNOV▲ +5.6%on this newsshared move
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Intracel
Read more →MNOVMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
LA JOLLA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s ongoin
Read more →MNOVMediciNova Reports Second Quarter 2021 Financial Results and Business Update
Initiated preclinical animal studies for MN-166 as a treatment for chlorine gas-induced induced lung disease under partnership with BARDA Positive Phase 2 results in alcohol use disorder published in Nature Journal reinforce safety and blockbuster potential of MN-166 Phase 2 re
Read more →MNOVSERVICES AGREEMENT This Agreement is entered into
This Agreement is entered into August 1, 2021 between Signature Analytics LLC ( SA ) and MediciNova, Inc. ( Client ) located at 4275 Executive Square, Suite 300, La Jolla, CA 92037. 1. Services. During the term of this Agreement, SA will provide financial and accounting servic
Read more →MNOVLEASE BETWEEN THE IRVINE COMPANY LLC AND MEDICINOVA, INC. LEASE (Short Form) THIS LEASE is made as of
THE IRVINE COMPANY LLC made as of July 20, 2021 , by and between THE IRVINE COMPANY LLC, a Delaware limited liability company, hereafter called Landlord, and MEDICINOVA, INC., a Delaware corporation, hereafter called Tenant. ARTICLE 1. BASIC LEASE PROVISIONS Each reference in
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease
LA JOLLA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chie
Read more →MNOVMediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
LA JOLLA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it will conduct a mouse study to investigate t
Read more →MNOVMediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal
LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of
Read more →MNOVMediciNova to Participate in Maxim Group LLC Fireside Chat
LA JOLLA, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chie
Read more →MNOVMediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate
Read more →MNOVMediciNova Reports First Quarter 2021 Financial Results and Business Update
- Completed $20M private placement financing with 3D Investment Partners - - Entered into partnership with BARDA to evaluate MN-166 for chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) - - Received $4M in milestone
Read more →MNOVMediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe
LA JOLLA, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to G
Read more →MNOVMediciNova Receives Gene Therapy Milestone Payments
LA JOLLA, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received two milestone payments u
Read more →MNOVMediciNova to Participate in the B. Riley Neuroscience Conference
LA JOLLA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chi
Read more →MNOVMediciNova to Participate in the UBS Global Healthcare Virtual Conference
LA JOLLA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the UBS G
Read more →MNOVMediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has partnered with the Biomedical Advanced
Read more →MNOVMediciNova to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
LA JOLLA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will present at the Inaugural
Read more →MNOVMediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19
LA JOLLA, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an update on the development of a SARS-CoV-2
Read more →MNOVMediciNova Announces Closing of US$20 Million Private Placement Transaction
MediciNova Announces Closing of US$20 Million Private Placement Transaction LA JOLLA, Calif., January 31, 2021 (GLOBE NEWSWIRE) MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan
LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners
MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners JOLLA, Calif., January 11, 2021 (GLOBE NEWSWIRE) MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS
LA JOLLA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Added to the NASDAQ Biotechnology Index
LA JOLLA, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will be added to the NASDAQ Bi
Read more →MNOVMediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published in Multiple Sclerosis Journal
LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive Optical Coherence Tomography (OC
Read more →MNOVMediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology
LA JOLLA, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Good Manufacturing Practice (GMP)-based M
Read more →MNOVMediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™ 2020
LA JOLLA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigators Leila Gobejishvil
Read more →MNOVMediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy
LA JOLLA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a multi-center, plac
Read more →MNOVMediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair
MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair LA JOLLA, Calif., October 21, 2020 (GLOBE NEWSWIRE) MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock
Read more →MNOVMediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020
LA JOLLA, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive findings from a study evaluating MN-0
Read more →MNOVMediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology
LA JOLLA, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive clinical findings published in Cance
Read more →MNOVMediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology
LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that its intranasal SARS-CoV-2 vaccine protot
Read more →MNOVMediciNova Announces that BioComo’s Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that BioComo, co-developer of MediciNova’s SA
Read more →MNOVMediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19
LA JOLLA, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced development progress on its intranasal SARS-C
Read more →MNOVMediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention
LA JOLLA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigator, Lara Ray, PhD, Pr
Read more →MNOVMediciNova to Participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
LA JOLLA, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the Morgan
Read more →MNOVMediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan
LA JOLLA, Calif., July 27, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an agreement with BioComo (President: Masayuki
Read more →MNOVMediciNova to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit
LA JOLLA, Calif., July 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President
Read more →MNOVMediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19
LA JOLLA, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Investigational New Drug Application
Read more →MNOVMediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology
LA JOLLA, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive preclinical findings published in Fro
Read more →MNOVMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Europe
LA JOLLA, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to
Read more →MNOVMediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
LA JOLLA, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fr
Read more →MNOVMediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)
LA JOLLA, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a clinical trial of MN-
Read more →MNOVMediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS)
LA JOLLA, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate development of MN-1
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan
LA JOLLA, Calif., Feb. 17, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe
LA JOLLA, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to
Read more →MNOVMediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia
LA JOLLA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional analyses of MediciNova’s compl
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
LA JOLLA, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan
LA JOLLA, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan
LA JOLLA, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China
LA JOLLA, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fr
Read more →MNOVMediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York
LA JOLLA, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chi
Read more →MNOVMediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
LA JOLLA, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will attend the Morgan Stanley
Read more →MNOVMediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan
LA JOLLA, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research
Read more →MNOVMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia
LA JOLLA, Calif., July 29, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s comple
Read more →MNOVMediciNova Appoints Kazuko Matsuda to its Board of Directors
MediciNova Appoints Kazuko Matsuda to its Board of Directors LA JOLLA, Calif., July 24, 2019 (GLOBE NEWSWIRE) MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), t
Read more →MNOVMediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its plans for a Phase 3 clinical trial of MN-1
Read more →MNOVMediciNova to Present at the JMP Securities Life Sciences Conference
LA JOLLA, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President
Read more →MNOVMediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS
LA JOLLA, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a kick-off meeting for the Phase 2b/3 cl
Read more →MNOVMediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
LA JOLLA, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Geoffrey O'Brien, JD/MBA, Vice President a
Read more →MNOVMediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom
LA JOLLA, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced its participation at the Kick-off Meeting for t
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
LA JOLLA, Calif., April 23, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the U.S. Food and Drug Administration (
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China
LA JOLLA, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fr
Read more →MNOVMediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced results from its subgroup analysis of the SPR
Read more →MNOVMediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania
LA JOLLA, Calif., March 24, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that additional data from the completed SPRIN
Read more →MNOVMediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan
LA JOLLA, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive researc
Read more →MNOVMediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports
LA JOLLA, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Scientific Reports has published results
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases
LA JOLLA, Calif., Jan. 21, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from
Read more →MNOVMediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma
LA JOLLA, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first glioblastoma patient has enroll
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan
LA JOLLA, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco
LA JOLLA, Calif., Dec. 12, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chie
Read more →MNOVMediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma
LA JOLLA, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA
Read more →MNOVMediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS
LA JOLLA, Calif., Sept. 25, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received positive feedback from the FD
Read more →MNOVMediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York
LA JOLLA, Calif., Sept. 18, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chi
Read more →MNOVMediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine
LA JOLLA, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the New England Journal of Medicine has p
Read more →MNOVMediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge
LA JOLLA, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a Phase 2/3 trial of
Read more →MNOVMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK
LA JOLLA, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s comple
Read more →MNOVMediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial
LA JOLLA, Calif., July 29, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing biomarker clinical trial of MN
Read more →MNOVMediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced clinical data from ad-hoc subgroup analyses of
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan
LA JOLLA, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from
Read more →MNOVMediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
LA JOLLA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the Investigational New Drug Application (I
Read more →MNOVMediciNova to Present at the UBS Global Healthcare Conference in New York
LA JOLLA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that MediciNova will present a corporate overvie
Read more →MNOVMediciNova Announces Plans to Collaborate with UCLA Researchers in Grant-Funded Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder and Withdrawal
LA JOLLA, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a clinical trial of M
Read more →MNOVMediciNova Announces Additional Data from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 70th Annual Meeting
LA JOLLA, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks,
Read more →MNOVMediciNova Announces the Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting Plenary Session with Additional Imaging Data
LA JOLLA, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Robert Fox, Staff Neurologist at the
Read more →MNOVMediciNova Announces Presentation of Significant Positive Results from Interim Analysis of the Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD at the International Liver Congress 2018 in Paris, France
LA JOLLA, Calif., April 13, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today presented the positive results from the interim analysi
Read more →MNOVMediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis
LA JOLLA, Calif., April 01, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will terminate the Phase 2 clinical t
Read more →MNOVMediciNova Announces Results of Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
LA JOLLA, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 clinical trial of MN-166 (ib
Read more →MNOVMediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy
LA JOLLA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a pilot study to eva
Read more →MNOVMediciNova to Participate in Business Development Panel Session at the BIO Asia International Conference in Tokyo
LA JOLLA, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that MediciNova will participate in a panel se
Read more →MNOVMediciNova to Present at the Cowen Health Care Conference in Boston
LA JOLLA, Calif., Feb. 25, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will present a corporate overv
Read more →MNOVMediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
LA JOLLA, Calif., Feb. 18, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the completed SPRIN
Read more →MNOVMediciNova Announces Closing of Underwritten Public Offering of Common Stock
LA JOLLA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today the closing of the previously announced underw
Read more →MNOVMediciNova Announces Pricing of Underwritten Public Offering of Common Stock
LA JOLLA, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced today the pricing of an underwritten public offering
Read more →MNOVMediciNova Announces Proposed Underwritten Public Offering of Common Stock
MediciNova Announces Proposed Underwritten Public Offering of Common Stock LA JOLLA, Calif., February 7, 2018 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), an
Read more →MNOVMediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression in the SPRINT-MS Phase 2b Trial in Progressive MS: Potential Best-in-Disease Drug
LA JOLLA, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the presentation of additional positive clinic
Read more →MNOVMediciNova Announces Presentation of the SPRINT-MS Phase 2b Study of MN-166 (ibudilast) in Progressive MS at the ACTRIMS Forum on February 1, 2018 in San Diego
LA JOLLA, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a presentation regarding the SPRINT-MS/NN
Read more →MNOVMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
LA JOLLA, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s comple
Read more →MNOVMediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France
LA JOLLA, Calif., Jan. 28, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding an interim analysis
Read more →MNOVMediciNova to Present at the 98th Annual Meeting of the Chemical Society of Japan
LA JOLLA, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova has accepted an invitation to
Read more →MNOVMediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive top-line results from MediciNova’s cl
Read more →MNOVMediciNova Announces Collaboration with the U.S. Department of Veterans Affairs and Oregon Health & Science University to Evaluate MN-166 (ibudilast) in Methamphetamine Use Disorder
LA JOLLA, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans initiate a biomarker study for e
Read more →MNOVMediciNova Appoints Hideki Nagao to its Board of Directors
MediciNova Appoints Hideki Nagao to its Board of Directors LA JOLLA, Calif., November 09, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875
Read more →MNOVMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA
LA JOLLA, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s ongoin
Read more →MNOVMediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved a Statistically Significant 48% Reduction in Whole Brain A
MediciNova Announces the Presentation of Additional Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved a Statistically Significant 48% Reduction in Whole Brain Atrophy with a Favorable Safety and Tolerability Profile L
Read more →MNOVMediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability
LA JOLLA, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the SPRINT-MS Phase 2b Trial of MN-166 (i
Read more →MNOVMediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
LA JOLLA, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 clinical trial of MN-166 (ib
Read more →MNOVMediciNova to Present at the Ladenburg Thalmann 2017 Healthcare Conference in New York
LA JOLLA, Calif., Sept. 18, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that Yuichi Iwaki, MD, PhD, President and Chie
Read more →MNOVMediciNova Announces the Abstract from the MN-166 (ibudilast) SPRINT-MS Phase 2b Study in Progressive MS - including Top Line Data - was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS - ACTRIMS Meeting on October 28, 2017 in Paris, France
LA JOLLA, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the SPRINT-MS/NN 10
Read more →MNOVMediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
LA JOLLA, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Associate Professor Kerrie McDonald, Head
Read more →MNOVMediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston
LA JOLLA, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that principal investigator Dr. Benjamin Rix
Read more →MNOVMediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois
LA JOLLA, Calif., April 09, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a mouse model stud
Read more →MNOVMediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland
LA JOLLA, Calif., Feb. 27, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that Associate Professor Kerrie McDonald, Head
Read more →MNOVMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston
LA JOLLA, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova’s ongoin
Read more →MNOVMediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research
LA JOLLA, Calif., Feb. 06, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced the presentation of results from a completed Ph
Read more →MNOVMediciNova to Attend Mizuho Healthcare Conference in New York
LA JOLLA, Calif., Feb. 01, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will attend the Mizuho Healthcare Conf
Read more →MNOVMediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence
LA JOLLA, Calif., Jan. 23, 2017 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the medical journal Neuropsychopharmacolog
Read more →MNOVMediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
LA JOLLA, Calif., Dec. 20, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the European Commission has granted Orphan
Read more →MNOVMediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned Following DSMB Review of Interim Efficacy Analysis
LA JOLLA, Calif., Dec. 19, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the external Data and Safety Monitoring B
Read more →MNOVMediciNova Added to NASDAQ Biotechnology Index
LA JOLLA, Calif., Dec. 14, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Company will be added to the NASDAQ B
Read more →MNOVMediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 27th International Symposium on ALS/MND in Dublin, Ireland
LA JOLLA, Calif., Dec. 09, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that principal investigator Dr. Benjamin Rix B
Read more →MNOVMediciNova to Present at the Piper Jaffray Healthcare Conference in New York
LA JOLLA, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chie
Read more →MNOVMediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
LA JOLLA, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the European Medicines Agency’s (EMA) Comm
Read more →MNOVCorporate Presentation November 2016 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of
Corporate Presentation Forward-Looking Statements presentation that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements incl
Read more →MNOVMediciNova to Attend Global Mizuho Investor Conference in New York
LA JOLLA, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will attend the Global Mizuho Investor
Read more →MNOVMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 27th International Symposium on ALS/MND in Dublin, Ireland
LA JOLLA, Calif., Oct. 30, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that an abstract regarding MediciNova’s ongoing
Read more →MNOVMediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Amyotrophic Lateral Sclerosis
LA JOLLA, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis
LA JOLLA, Calif., July 24, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Announces Initiation of Interim Efficacy Analysis in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., July 13, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that 50% of patients (127 out of 255 enrolled
Read more →MNOVMediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
LA JOLLA, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that researchers at the University of Californi
Read more →MNOVMediciNova Added to Russell 3000 Index and Russell Global Index
LA JOLLA, Calif., June 26, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the Company has been added to the Russell
Read more →MNOVMediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
LA JOLLA, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that two abstracts detailing novel findings from
Read more →MNOVMediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada
LA JOLLA, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks,
Read more →MNOVMediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence
LA JOLLA, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the medical journal Drug and Alcohol Dep
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 in China
LA JOLLA, Calif., March 27, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a notice of allowance fr
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia
LA JOLLA, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
LA JOLLA, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas
LA JOLLA, Calif., March 06, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced the presentation of results based on the compl
Read more →MNOVMediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada
LA JOLLA, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that an abstract regarding MediciNova's ongoing
Read more →MNOVMediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas
LA JOLLA, Calif., Feb. 11, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that principal investigator Keith Heinzerling,
Read more →MNOVMediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas
LA JOLLA, Calif., Feb. 07, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that principal investigator Sandra Comer, Ph.D.
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH With Fibrosis
LA JOLLA, Calif., Jan. 27, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in Europe
LA JOLLA, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced receipt from the European Patent Office of a no
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride in China
LA JOLLA, Calif., Dec. 14, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a notice of allowance for
Read more →MNOVMediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL
LA JOLLA, Calif., Dec. 13, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that principal investigator Dr. Benjamin Rix Brooks,
Read more →MNOVMediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
LA JOLLA, Calif., Dec. 09, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Daniel Roche today presented results based
Read more →MNOVMediciNova Announces Presentation Regarding Clinical Trial of MN-166 (ibudilast) in ALS at the 6th Annual California ALS Pac10 and Research Network Meeting at UCSD, La Jolla, California
LA JOLLA, Calif., Dec. 06, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that Dr. Yuichi Iwaki, President and CEO, has accepte
Read more →MNOVMediciNova to Initiate Clinical Trial Evaluating MN-001 in NASH Patients With Hypertriglyceridemia
LA JOLLA, Calif., Nov. 19, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it is initiating a clinical trial to investiga
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan
LA JOLLA, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova Announces Interim Data From Clinical Trial of MN-166 (ibudilast) in ALS to be Presented at the 14th Annual NEALS (Northeast Amyotrophic Lateral Sclerosis) Meeting in Clearwater Beach, Florida
LA JOLLA, Calif., Nov. 04, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), announced that Dr. Benjamin Rix Brooks, Principal Investigator,
Read more →MNOVMediciNova to Present Preclinical Data on MN-166 (ibudilast) at the 26th International Symposium on ALS/MND in Orlando, FL
LA JOLLA, Calif., Oct. 13, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will present preclinical data on MN-16
Read more →MNOVMediciNova to Initiate Clinical Trial of MN-001 (tipelukast) in IPF
LA JOLLA, Calif., Oct. 09, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that following completion of an agreement with
Read more →MNOVMediciNova, Inc. 2015 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform A
Tipelukast MN 001 MN 001 LOXL2 Cross linking of collagen and elastin fibrosis Collagen Type 1 CCR2 MCP 1 TIMP 1 MN 001 Reduces Gene Expression LOXL2 Collagen Type 1 CCR2 MCP 1 TIMP 1 MediciNova, Inc. 2015 More than 600 human subjects exposed to MN 001 Phase 2 study of MN 001 in a
Read more →MNOVMediciNova to Present at the Ladenburg Thalmann 2015 Healthcare Conference
LA JOLLA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that Yuichi Iwaki, MD, PhD, President and Chie
Read more →MNOVMediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast)
LA JOLLA, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first advanced ALS patient, using non
Read more →MNOVMediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia
LA JOLLA, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that FDA (U.S. Food and Drug Administration) ha
Read more →MNOVMediciNova Announces Update on Development Plans for MN-001 in IPF
LA JOLLA, Calif., July 21, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it is currently in late-stage discussions with
Read more →MNOVMediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence
LA JOLLA, Calif., June 30, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the clinical trial of MN-166 (ibudilast)
Read more →MNOVMediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting
LA JOLLA, Calif., June 24, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that principal investigator Lara Ray, Ph.D., A
Read more →MNOVMediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology
LA JOLLA, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the medical journal Addiction Biology has
Read more →MNOVMediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., June 12, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the ongoing clinical trial of MN-166 (ibu
Read more →MNOVMediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease
LA JOLLA, Calif., June 3, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA)
Read more →MNOVMediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has been notified by NINDS (National Ins
Read more →MNOVMediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced that Dr. Benjamin Rix Brooks, principal investigato
Read more →MNOVMediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at the AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease in Durham, North Carolina
LA JOLLA, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has been invited to and will present da
Read more →MNOVMediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS
LA JOLLA, Calif., Feb. 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the ongoing clinical trial of MN-166 (ibud
Read more →MNOVMediciNova Announces FDA Approval of Protocol for Phase 2 Trial of MN-001 in IPF
LA JOLLA, Calif., Feb. 10, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that FDA (U.S. Food and Drug Administration) h
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of NASH
LA JOLLA, Calif., Feb. 3, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from
Read more →MNOVMediciNova Receives New Patent Covering MN-029 (denibulin) di-hydrochloride in Japan
LA JOLLA, Calif., Jan. 29, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a new patent from the Jap
Read more →MNOVMediciNova Announces an Open Investigational New Drug (IND) Application for MN-001 in NASH
LA JOLLA, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the IND (Investigational New Drug) Applic
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Liver Disorders
LA JOLLA, Calif., Dec. 9, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from
Read more →MNOVMediciNova Announces FDA Granted Orphan Drug Designation to MN-001 (tipelukast) for Idiopathic Pulmonary Fibrosis (IPF)
LA JOLLA, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that the U.S. Food and Drug Administration (FDA
Read more →MNOVMediciNova, Inc. 2014 MediciNova, Inc. 2014 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securiti
NAFLD Activity Score (NAS) % of fibrosis area Tipelukast MN 001 MediciNova, Inc. 2014 MediciNova, Inc. 2014 Next Steps Progressive MS 15 Q2 2013: Submit New IND Amendment and New Ph2 Protocol Q3 2013: FDA approval Study Initiation Q3 2013: Screening begins Q4 2013: First Patient
Read more →MNOVMediciNova Receives Feedback From FDA Regarding Study Protocol for Phase 2 Trial of MN-001 (tipelukast) in NASH
LA JOLLA, Calif., Oct. 8, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received feedback from FDA's Divisio
Read more →MNOVMediciNova's MN-001 (tipelukast) NASH Abstract Selected for Late-Breaking Session at the 65th Annual AASLD Meeting in Boston
LA JOLLA, Calif., Oct. 6, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has been invited to and will present dat
Read more →MNOVMediciNova Provides Update on Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
LA JOLLA, Calif., Sept. 23, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that, as of September 15, 2014, the ongoing P
Read more →MNOVMediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence
LA JOLLA, Calif., Sept. 7, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that Columbia University and the New York State
Read more →MNOVMediciNova to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)
LA JOLLA, Calif., Sept. 1, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it will present at the 18th International
Read more →MNOVMediciNova to Initiate Clinical Trial of MN-166 (ibudilast) in ALS
LA JOLLA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the FDA approval to initiate a clinical trial
Read more →MNOVMediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid Dependence
MediciNova Announces Positive Interim Results of Phase 2a Study of MN-166 (ibudilast) in Opioid LA JOLLA, Calif., August 18, 2014 (GLOBE NEWSWIRE) MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Trading Symbol: MNOV) and the JASDAQ Market of the
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Nonalcoholic Fatty Liver Disease
LA JOLLA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from
Read more →MNOVMediciNova Announces Positive Results of MN-001 in Advanced NASH Mouse Model; MediciNova Requests a Meeting With FDA
LA JOLLA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a second preclinical stud
Read more →MNOVMediciNova to Present Data on MN-001 for the Treatment of NASH (Nonalcoholic Steatohepatitis) During the JDDW 2014 (Japan Digestive Disease Week 2014)
LA JOLLA, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will present at the 56th Annual Meeting
Read more →MNOVMediciNova Announces Positive Results in Study of MN-001 in Mouse Model of Pulmonary Fibrosis
SAN DIEGO, June 11, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a study that examined the poten
Read more →MNOVMediciNova Announces Management Appointment
SAN DIEGO, April 8, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Esther van den Bo
Read more →MNOVMediciNova Appoints Yoshio Ishizaka to its Board of Directors
MediciNova Appoints Yoshio Ishizaka to its Board of Directors SAN DIEGO, April 8, 2014 (GLOBE NEWSWIRE) MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today an
Read more →MNOVMediciNova Announces Positive Results in NASH Mouse Model With MN-001 and Prepares to Initiate Phase 2 Trial in the U.S.
SAN DIEGO, Jan. 14, 2014 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive results from a study that examined the poten
Read more →MNOVMediciNova Receives New Patent Covering MN-221 in Irritable Bowel Syndrome
SAN DIEGO, Nov. 11, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), announced that a new U.S. patent has been granted wh
Read more →MNOVMediciNova Reports Third Quarter 2013 Results
SAN DIEGO, Nov. 7, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number:4875), today announced financial results for the third quarter ended September
Read more →MNOVMediciNova Appoints Geoffrey O'Brien as Vice President
SAN DIEGO, Oct. 16, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Geoffrey O'Brien,
Read more →MNOVMediciNova Appoints Yutaka Kobayashi to its Board of Directors
MediciNova Appoints Yutaka Kobayashi to its Board of Directors SAN DIEGO, Oct 16, 2013 (GLOBE NEWSWIRE) MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering MN-029 (denibulin) di-hydrochloride
SAN DIEGO, Oct. 6, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), announced that it has received a Notice of Allowance
Read more →MNOVMediciNova Reports Second Quarter 2013 Results
SAN DIEGO, Aug. 8, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the second quarter ended Jun
Read more →MNOVMediciNova Announces Initiation of a Cooperative Phase 2b Trial of MN-166 in Progressive Multiple Sclerosis
SAN DIEGO, July 18, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the funding and regulatory approvals
Read more →MNOVMediciNova, Inc. 2013 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform A
(2) A non addictive treatment would fill an unmet need in this large market MN 166 (ibudilast): MN 166 (ibudilast): A Novel Oral Therapy A Novel Oral Therapy for the Treatment of for the Treatment of Progressive Multiple Sclerosis (MS) Progressive Multiple Sclerosis (MS) 24 25 MN
Read more →MNOVM EDICI N OVA , I NC . 2013 E QUITY I NCENTIVE P LAN A DOPTED BY THE B OARD OF D IRECTORS : A PRIL 21, 2013 A PPROVED BY THE S TOCKHOLDERS : J UNE 14, 2013 1. G ENERAL . (a) Successor to and Continuation of Prior Plan. T
EQUITY INCENTIVE PLAN THE BOARD OF DIRECTORS: APRIL 21, 2013 APPROVED BY THE STOCKHOLDERS: JUNE 14, 2013 (a) Successor to and Continuation of Prior Plan. The Plan is intended as the successor to and continuation of the MediciNova, Inc. Amended and Restated 2004 Stock Incentive
Read more →MNOVMediciNova Reports First Quarter 2013 Results
SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the first quarter ended March
Read more →MNOVMediciNova Reports Fourth Quarter and Full Year 2012 Results
MediciNova Reports Fourth Quarter and Full Year 2012 Results SAN DIEGO, Calif. March 28, 2013 MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Trading Symbol: MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today
Read more →MNOVMediciNova Announces MN-166 (ibudilast) Opioid Withdrawal and Analgesia Data Presentation at the American Academy of Neurology Annual Meeting
SAN DIEGO, March 20, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that data from a Phase 1b/2a s
Read more →MNOVMediciNova Provides Development Update
SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), provides a development update on its two lead pr
Read more →MNOVMediciNova Receives Notice of Patent Allowance for Method of Treating Acute Exacerbations of Asthma
SAN DIEGO, Dec. 9, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced that it has been granted a Notice of A
Read more →MNOVMediciNova Announces Initiation of a Clinical Trial of MN-166 in Opioid Abusers With Columbia University and the New York State Psychiatric Institute
SAN DIEGO, Nov. 20, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced the initiation of enrollment of a Phase 2a clinical tri
Read more →MNOVMediciNova Extends MN-166 Patent Position in Europe
SAN DIEGO, Nov. 18, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received Notices of Allowance from the
Read more →MNOVMediciNova to Present at the Fourth World Congress of Emergency Medicine
SAN DIEGO, Nov. 14, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced that Dr. Kazuko Matsuda, Chief Medical Officer, will pr
Read more →MNOVMediciNova Announces Publication of MN-221 Clinical Results in Journal of Asthma
SAN DIEGO, Nov. 12, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the publication of positive Phase 2 clinical resu
Read more →MNOVMediciNova Reports Third Quarter 2012 Results and Update on MN-221 Development
SAN DIEGO, Nov. 8, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), yesterday reported financial results for the thi
Read more →MNOVMediciNova to Present at the Lazard Capital Markets Healthcare Conference
SAN DIEGO, Nov. 7, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Dr. Yuichi Iwaki, President and Chief Executiv
Read more →MNOVMediciNova Receives a Notice of European Patent Allowance for Treating Progressive Multiple Sclerosis
SAN DIEGO, Oct. 25, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from th
Read more →MNOVMediciNova Meets With FDA for End-of-Phase 2 Meeting for MN-221 for the Treatment of Acute Exacerbations of Asthma
SAN DIEGO, Oct. 22, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it conducted an End-of-Phase 2 meeting pert
Read more →MNOVMediciNova to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11, 2012
SAN DIEGO, Aug. 28, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced that Dr. Yuichi Iwaki, President and
Read more →MNOVMediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat-Dose Clinical Trial With MN-221 in Chronic Obstructive Pulmonary Disease Patients
SAN DIEGO, Aug. 23, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced positive preliminary results of a Pha
Read more →MNOVMediciNova Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund Aspire Capital Fund Makes Initial Investment of $1 Million
MediciNova Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund Aspire Capital Fund Makes Initial Investment of $1 Million Calif. August 20, 2012 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Tr
Read more →MNOVMediciNova Reports Second Quarter 2012 Results
SAN DIEGO, Aug. 9, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), yesterday reported financial results for the sec
Read more →MNOVA ccelerating Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 19
Muzio L., Martino G., et al. (2007). Multifaceted Aspects of Inflammation in Multiple Sclerosis: The Role of Microglia . J Neuroimmunol 2007; 191(1 2): 39 44. Rolan, P., Hutchinson, M., and Johnson, K. Ibudilast: A Review of its Safety, Efficacy, and Pharmacology in Respiratory a
Read more →MNOVMediciNova Announces Scheduling of End-of-Phase 2 Meeting With FDA for MN-221 for the Treatment of Acute Exacerbations of Asthma
SAN DIEGO, July 2, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that an End-of-Phase 2 meeting pertaining to the
Read more →MNOVMediciNova to Present at the JMP Securities Seventh Annual Healthcare Conference
SAN DIEGO, July 2, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced today that Dr. Yuichi Iwaki, President & CEO, will prese
Read more →MNOVMediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma Exacerbations
Company Intends to Move Forward With End-of-Phase 2 Meeting With FDA and Phase 3 Clinical Development Management to Host Conference Call to Discuss Results Today, May 23rd at 5:00pm (EDT) SAN DIEGO, May 23, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company t
Read more →MNOVMediciNova Reports First Quarter 2012 Results
SAN DIEGO, May 10, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), announced financial results for the first quarter ended March 31,
Read more →MNOVMediciNova Receives Notice of an Australian Patent Allowance for a Method of Treating Neuropathic Pain
SAN DIEGO, April 23, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from t
Read more →MNOVMediciNova Appoints David O Toole CPA to its Board of Directors
MediciNova Appoints David O Toole CPA to its Board of Directors SAN DIEGO, Calif. April 10, 2012 MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Trading Symbol: MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), to
Read more →MNOVMediciNova Reports Fourth Quarter and Full Year 2011 Results MediciNova Management to Host a Conference Call to Discuss 2011 Earnings Tomorrow, March 29 th at 5:00pm (EDT)
MediciNova Reports Fourth Quarter and Full Year 2011 Results MediciNova Management to Host a Conference Call to Discuss 2011 Earnings Tomorrow, March 29th at 5:00pm (EDT) SAN DIEGO, Calif. March 28, 2011 MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global
Read more →MNOVMediciNova Management to Host a Conference Call to Discuss 2011 Earnings Thursday, March 29th at 5:00 P.M. (EDT)
SAN DIEGO, March 22, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced it will report fourth quarter and year end 2011
Read more →MNOVMediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients Suffering from Acute Exacerbations of Asthma
SAN DIEGO, March 21, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc. a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced it has completed enrollment in its Phase 2 clinical trial (MN
Read more →MNOVMediciNova Receives Notice of a Japanese Patent Allowance for a Method of Treating Neuropathic Pain
SAN DIEGO, March 13, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from
Read more →MNOVMediciNova, Inc. 2012 Forward Looking Statements Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Sec
Pail Rolan at Univ. of Adelaide, Australia; reduced headache index, acute medication (codeine) use and headache impact on Quality of Life (QOL); 8 week trial + follow up; n = 20 patients each at placebo vs. 80 mg/day of MN 166 Acquired rights to treatment of post traumatic brain
Read more →MNOVMediciNova to Present at American Academy of Emergency Medicine Annual Meeting
SAN DIEGO, Feb. 8, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), will be presenting at the 18th annual American Academy of Emergency Medicine (AA
Read more →MNOVMediciNova Receives a Notice of Patent Allowance for a Method of Treating Progressive Multiple Sclerosis
SAN DIEGO, Calif., Feb. 1, 2012 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced that it has received a Notice of Allowance from the U.S.
Read more →MNOVMediciNova and University of Colorado Boulder Collaborate on Potential Novel Therapy for Traumatic Brain Injury
SAN DIEGO, Jan. 16, 2012 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), and the University of Colorado (CU) Boulder disclosed a lice
Read more →MNOVMediciNova, Inc. Appoints Kousuke Nakata to Its Board of Directors
SAN DIEGO, Calif., Nov. 30, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced the appointment of Mr. Kousuke Nakata CPA to its Boar
Read more →MNOVMediciNova Reports Third Quarter 2011 Results MediciNova Management to Host a Conference Call to Discuss Third Quarter 2011 Results Today, November 15, at 4:30pm (EST)
MediciNova Reports Third Quarter 2011 Results MediciNova Management to Host a Conference Call to Discuss Third Quarter 2011 Results Today, November 15, at 4:30pm (EST) SAN DIEGO, Calif. November 15, 2011 MediciNova, Inc., a biopharmaceutical company that is publicly traded on
Read more →MNOVMediciNova Reports Third Quarter 2011 Results
SAN DIEGO, Nov. 15, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), yesterday reported financial results for the th
Read more →MNOVMediciNova Announces Repeat Dose Clinical Trial With MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
SAN DIEGO, Oct. 27, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), announced initiation of a Phase 1b clinical trial with MN-221 in patients wit
Read more →MNOVMediciNova to Receive $2.5 Million Payment From Kissei Pharmaceutical Co. Ltd. to Expand Clinical Development of the MN-221 Program
SAN DIEGO, Oct. 13, 2011 (GLOBE NEWSWIRE) -- MediciNova Inc., a biopharmaceutical company publicly traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced that Kissei Pharmaceutical Co. Ltd., a pharmaceutical
Read more →MNOVMediciNova Closes $7.5 Million Private Stock Sale to Kissei Pharmaceutical Co., Ltd.
SAN DIEGO, Oct. 12, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), announced it has closed the private stock sale to Kissei Pharmaceutical Co.,
Read more →MNOVMediciNova, Inc. Announces Private Sale of Stock to Kissei Pharmaceutical Co., Ltd.
SAN DIEGO, Sept. 26, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced a private offering of common stock and Series B convertible
Read more →MNOVMediciNova, Inc. Appoints Mr. Tatsuo Izumi to Its Board of Directors
SAN DIEGO, Sept. 26, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announced the appointment of Mr. Tatsuo Izumi to its Board of Director
Read more →MNOVMediciNova Announces Management Appointments
SAN DIEGO, Sept. 2, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced the appointments of Kazuko Mats
Read more →MNOVMediciNova Reports Second Quarter 2011 Results
SAN DIEGO, Aug. 16, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), yesterday reported financial results for the se
Read more →MNOVMediciNova Reports Second Quarter 2011 Results MediciNova Management to Host a Conference Call to Discuss Second Quarter 2011 Results Today, August 16, at 4:30pm (EDT)
MediciNova Reports Second Quarter 2011 Results MediciNova Management to Host a Conference Call to Discuss Second Quarter 2011 Results Today, August 16, at 4:30pm (EDT) SAN DIEGO, Calif. August 16, 2011 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the
Read more →MNOVMediciNova Announces Second Quarter 2011 Earnings Conference Call and Webcast
SAN DIEGO, Aug. 11, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), today announced it will report second quarter 2
Read more →MNOVMediciNova to Collaborate on a Phase 2 Trial of Ibudilast (MN-166/AV411) in Medication Overuse Headache
SAN DIEGO, Aug. 10, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), disclosed a clinical trial collaboration with P
Read more →MNOVMediciNova Reports First Quarter 2011 Results
SAN DIEGO, May 17, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number: 4875), yesterday reported financial results for the fir
Read more →MNOVMediciNova Reports First Quarter 2011 Results MediciNova Management to Host a Conference Call to Discuss First Quarter 2011 Results Today, May 17, at 4:30pm(EDT)
MediciNova Reports First Quarter 2011 Results MediciNova Management to Host a Conference Call to Discuss First Quarter 2011 Results Today, May 17, at 4:30pm(EDT) SAN DIEGO, Calif. May 17, 2011 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq
Read more →MNOVMediciNova Announces First Quarter 2011 Earnings Conference Call and Webcast
SAN DIEGO, May 11, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number:4875), today announced it will report first quarter 2011
Read more →MNOVMediciNova to Host Business Update Conference Call by Management on April 7, 2011
SAN DIEGO, April 6, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number:4875), today announced its plans to host a business upd
Read more →MNOVMediciNova Reports Fourth Quarter and Full Year 2010 Results
MediciNova Reports Fourth Quarter and Full Year 2010 Results SAN DIEGO, Calif. March 31, 2011 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Nu
Read more →MNOVMediciNova Prices $8.25 Million Public Offering of Common Stock and Warrants
SAN DIEGO, March 23, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), announced that it has priced a firm-commitment underwritten public offering
Read more →MNOVMediciNova Announces Proposed Public Offering of Common Stock and Warrants San Diego, CA
MediciNova Announces Proposed Public Offering of Common Stock and Warrants San Diego, CA, March 23, 2011 MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq: MNOV) and the Jasdaq Market of the Osaka Securities Exchange (4875), today announce
Read more →MNOVMediciNova Receives a Notice of Allowance for a Method of Treating Drug Addiction or Dependence
SAN DIEGO, March 9, 2011 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance fro
Read more →MNOVMediciNova, Inc. 2011 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform A
MN 221 may result in fewer cardiovascular side effects than the current standard of care 40 MediciNova, Inc. 2011 Since the average hospitalization cost is $6,477 in the US, the payor would save this amount for each hospitalization prevented. Since US hospitals lose money on the
Read more →MNOVMediciNova, Inc. 2011 Forward Looking Statements Forward Looking Statements Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor pr
Secure a global partnership for Ibudilast (MN 166/AV411) 2. Secure a strategic partnership for MN 221 Upcoming Clinical Milestones: 1. MN 221 CL 007 Phase II Study for Acute Exacerbations of Asthma Anticipated completion in 2H, 2011* Completed Milestones in 2010: 1. Announced Pos
Read more →MNOVColumbia University/New York State Psychiatric Institute and MediciNova Report Preliminary Safety and Efficacy of Ibudilast in Heroin-dependent Volunteers First Trial of a Glial Cell Modulator in Drug Addicts San Diego,
Columbia University/New York State Psychiatric Institute and MediciNova Report Preliminary Safety and Efficacy of Ibudilast in Heroin-dependent Volunteers First Trial of a Glial Cell Modulator in Drug Addicts San Diego, CA December 13, 2010 Drug addiction investigators with jo
Read more →MNOVMediciNova Reports Third Quarter 2010 Results
MediciNova Reports Third Quarter 2010 Results SAN DIEGO, Calif. November 15, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875
Read more →MNOVMediciNova's MN-166 Program Recognized as One of Windhover's Top 10 Neuroscience Projects to Watch
SAN DIEGO, Oct. 19, 2010 (GLOBE NEWSWIRE) -- MediciNova Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Jasdaq Market of the Osaka Securities Exchange (Code Number:4875), announced today that its novel macrophage migration inhibi
Read more →MNOVMediciNova, Inc. 2010 Forward Looking Statements Forward Looking Statements 2 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor
MN 221 CL 007 Phase II Study for Acute Exacerbations of Asthma Anticipated completion 1Q, 2011* 2. MN 166 Study for Opioid Withdrawal Anticipated completion in 2H, 2010* Potential upcoming Business Deals: 1. Secure a global partnership for MN 166 2. Secure a strategic partnership
Read more →MNOVMediciNova, Inc. 2010 Forward Looking Statements Forward Looking Statements Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor pr
Secure a global partnership for MN 166 2. Secure a strategic partnership for MN 221 Upcoming Clinical Milestones: 1. MN 221 CL 007 Phase II Study for Acute Exacerbations of Asthma Anticipated completion 1Q, 2011* 2. MN 166 Study for Opioid Withdrawal Anticipated completion in 2H,
Read more →MNOVMediciNova to Present at the Rodman and Renshaw Annual Global Investment Conference
SAN DIEGO, Sept. 2, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Shintaro Asako, Chief Fi
Read more →MNOVMediciNova Reports Second Quarter 2010 Results
MediciNova Reports Second Quarter 2010 Results SAN DIEGO, Calif. August 16, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875)
Read more →MNOVMediciNova Announces Estimated Timing of Payments to Former Avigen Stockholders
SAN DIEGO, July 12, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it expects to make an in
Read more →MNOVMediciNova Nets $9.5 Million from Settlement of Auction Rate Securities Held by
MediciNova Nets $9.5 Million from Settlement of Auction Rate Securities Held by UBS SAN DIEGO, Calif. July 6, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Secur
Read more →MNOVMediciNova Appoints Michael Coffee as Chief Business Officer
SAN DIEGO, June 14, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Michael Coffee has joined
Read more →MNOVMediciNova Reports First Quarter 2010 Results
MediciNova Reports First Quarter 2010 Results SAN DIEGO, Calif. May 17, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), to
Read more →MNOVMediciNova Secures $15 Million Debt Facility From Oxford Finance Corporation
MediciNova Secures $15 Million Debt Facility From Oxford Finance Corporation SAN DIEGO, Calif. May 11, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities E
Read more →MNOVSUPERIOR COURT FOR THE STATE OF CALIFORNIA FOR THE COUNTY OF ALAMEDA THE PENNSYLVANIA AVENUE FUNDS, individually and on behalf of all others similarly situated, Case No. RG09470224 Plaintiff, STIPULATION OF SETTLEMENT v.
SUPERIOR COURT FOR THE STATE OF CALIFORNIA FOR THE COUNTY OF ALAMEDA THE PENNSYLVANIA AVENUE FUNDS, individually and on behalf of all others similarly situated, Case No. RG09470224 Plaintiff, STIPULATION OF SETTLEMENT v. Judge Steven A. Brick AVIGEN, INC.; ZOLA HOROVITZ;
Read more →MNOVMediciNova Reports Fourth Quarter and Full Year 2009 Results
MediciNova Reports Fourth Quarter and Full Year 2009 Results SAN DIEGO, Calif. March 24, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code
Read more →MNOVMediciNova, Inc. 2010 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform A
Secure a global partnership for MN 166 2. Secure a regional partnership (ex US/Japan rights) for MN 221 Upcoming Clinical Milestones: 1. MN 221 CL 007 Phase II Study for Acute Exacerbations of Asthma Anticipated completion 2H, 2010* 2. MN 166 Study for Opioid Withdrawal Anticipat
Read more →MNOVMediciNova Reports Positive Preliminary Results from a Phase Ib Clinical Trial of MN-221 in Moderate to Severe COPD Patients
MediciNova Reports Positive Preliminary Results from a Phase Ib Clinical Trial of MN-221 in Moderate to Severe COPD Patients SAN DIEGO, Calif. March 17, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV)
Read more →MNOVMediciNova Appoints Dr. Kirk Johnson Chief Scientific Officer
SAN DIEGO, Feb. 1, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Kirk Johnson, Ph.D. has jo
Read more →MNOVAccelerating the global development and commercialization of innovative pharmaceuticals MediciNova, Inc. 2010 Forward Looking Statements Forward Looking Statements Statements in this presentation that are not historical
Secure a global partnership for MN 166 (AV411) 2. Secure a regional partnership (ex US/Japan rights) for MN 221 Clinical Milestones: 1. MN 221 CL 007 Phase II Study for Acute Exacerbations of Asthma Anticipated completion 2H, 2010* 2. MN 221 CL 010 Phase Ib Study in Moderate to S
Read more →MNOVMediciNova Extends Conversion Deadline to January 11, 2010
SAN DIEGO, Jan. 5, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that it has extended the deadli
Read more →MNOVMediciNova Extends Conversion Deadline to
MediciNova Extends Conversion Deadline to January 11, 2010 SAN DIEGO, Calif., January 5, 2010 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:48
Read more →MNOVMediciNova Completes Acquisition of Avigen
SAN DIEGO, Dec. 18, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that it has completed its acqu
Read more →MNOVMediciNova and Avigen Stockholders Approve Merger
SAN DIEGO and ALAMEDA, Calif., Dec. 17, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875) and Avigen, Inc. (Nasdaq:AV
Read more →MNOVMEDICINOVA AND AVIGEN STOCKHOLDERS APPROVE MERGER SAN DIEGO, Calif., and
MEDICINOVA AND AVIGEN STOCKHOLDERS APPROVE MERGER SAN DIEGO, Calif., and ALAMEDA, Calif., December 17, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (
Read more →MNOVMEDICINOVA AND AVIGEN CONFIRM STOCKHOLDER ELECTION DEADLINE SAN DIEGO, Calif., and
MEDICINOVA AND AVIGEN CONFIRM STOCKHOLDER ELECTION DEADLINE SAN DIEGO, Calif., and ALAMEDA, Calif., December 15, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities
Read more →MNOVMEDICINOVA AND AVIGEN ANNOUNCE STOCKHOLDER ELECTION DEADLINE AND UPDATE TO ESTIMATED MERGER CONSIDERATION SAN DIEGO, Calif., and
MEDICINOVA AND AVIGEN ANNOUNCE STOCKHOLDER ELECTION DEADLINE AND UPDATE TO ESTIMATED MERGER CONSIDERATION SAN DIEGO, Calif., and ALAMEDA, Calif., December 9, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and
Read more →MNOVMediciNova, Inc. 2009 Forward Looking Statements Forward Looking Statements Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor pr
Secure a global partnership for MN 166/AV 411 combined package* 2. Secure a regional partnership (ex US/Japan rights) for MN 221 Clinical Milestones: 1. MN 221 CL 007 Phase II study for Acute Exacerbations of Asthma Anticipated completion 2H, 2010** 2. MN 221 CL 010 Phase Ib stud
Read more →MNOVMediciNova Reports Third Quarter 2009 Results
SAN DIEGO, Calif., Nov. 12, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for
Read more →MNOVShintaro Asako Chief Financial Officer Phone: (858) 373-1500 E-mail: info@medicinova.com FOR IMMEDIATE RELEASE MediciNova Reports Third Quarter 2009 Results
MediciNova Reports Third Quarter 2009 Results November 12, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced
Read more →MNOVMediciNova Announces Initiation of a Phase Ib Clinical Trial for MN-221 in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease
SAN DIEGO, Nov. 3, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the initiation of a Phase Ib c
Read more →MNOVMediciNova, Inc. Appoints Mr. Hiroaki Shigeta to Its Board of Directors
SAN DIEGO, Sept. 16, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the appointment of Mr. Hiroa
Read more →MNOVShintaro Asako Chief Financial Officer Phone: (858) 373-1500 E-mail: info@medicinova.com Rhonda Chiger Rx Communications Group, LLC Phone: (917) 322-2569 E-mail: rchiger@rxir.com FOR IMMEDIATE RELEASE MediciNova
CONTACT: Shintaro Asako Chief Financial Officer Phone: (858) 373-1500 E-mail: info@medicinova.com Rhonda Chiger Rx Communications Group, LLC Phone: (917) 322-2569 E-mail: rchiger@rxir.com MediciNova, Inc. Appoints Mr. Hiroaki Shigeta To Its Board of Directors SAN DIEGO, Ca
Read more →MNOVMediciNova to Present At the Rodman and Renshaw Annual Global Investment Conference
SAN DIEGO, Sept. 4, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Shintaro Asako, Chief Fi
Read more →MNOVMediciNova, Inc. 2009 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform A
Sales 2008** Compound Sponsor Side Effects $2.3 Billion Copaxone Teva Sanofi Aventis Pain, redness, swelling, itching, chest pain, weakness, infection, nausea, anxiety are most common, also heart palpitations and trouble breathing after injection $2.2 Billion Avonex Biogen Idec D
Read more →MNOVMediciNova and Avigen Enter Into Definitive Agreement for Business Combination SAN DIEGO, Calif., and
MediciNova and Avigen Enter Into Definitive Agreement for Business Combination SAN DIEGO, Calif., and ALAMEDA, Calif., August 21, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the
Read more →MNOVMediciNova Reports Second Quarter 2009 Results
SAN DIEGO, Aug. 14, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the sec
Read more →MNOVMediciNova to Evaluate MN-221 for the Treatment of Chronic Obstructive Pulmonary Disease Exacerbations
SAN DIEGO, July 20, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it plans to evaluate MN-
Read more →MNOVShintaro Asako Chief Financial Officer Phone: 858-373-1500 E-mail: info@medicinova.com Rhonda Chiger Rx Communications, LLC Phone: (917) 322-2569 E-mail: rchiger@rxir.com FOR IMMEDIATE RELEASE MediciNova Announc
MediciNova Announces Proposed Final Protocol for its Phase II Placebo-controlled Evaluating MN-221 in Patients with Severe, Acute Exacerbations of Asthma SAN DIEGO, CA. July 13, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Mar
Read more →MNOVMediciNova Announces Proposed Final Protocol for Its Phase II Placebo-Controlled Clinical Trial Evaluating MN-221 in Patients With Severe, Acute Exacerbations of Asthma
SAN DIEGO, July 13, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the proposed final protocol f
Read more →MNOVMediciNova and Avigen Confirm Understanding for Key Terms for a Business Combination SAN DIEGO, Calif., and
MediciNova and Avigen Confirm Understanding for Key Terms for a Business Combination SAN DIEGO, Calif., and ALAMEDA, Calif., June 25, 2009 (GLOBE NEWSWIRE) MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the He
Read more →MNOVShintaro Asako Chief Financial Officer Phone: (858) 373-1500 E-mail: info@medicinova.com Rhonda Chiger Rx Communications, LLC Phone: (917) 322-2569 E-mail: rchiger@rxir.com FOR IMMEDIATE RELEASE Arlene Morris Jo
Arlene Morris Joins MediciNova s Audit Committee SAN DIEGO, CA. June 22, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), t
Read more →MNOVShintaro Asako Chief Financial Officer Phone: (858) 373-1500 E-mail: info@medicinova.com Rhonda Chiger Rx Communications, LLC Phone: (917) 322-2569 E-mail: rchiger@rxir.com FOR IMMEDIATE RELEASE MediciNova Annou
MediciNova Announces Plan to Modify its Phase II Placebo-controlled Clinical Trial Evaluating MN-221 in Patients with Severe, Acute Exacerbations of Asthma SAN DIEGO, CA. May 28, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global
Read more →MNOVMediciNova Announces Plan to Modify Its Phase II Placebo-Controlled Clinical Trial Evaluating MN-221 in Patients With Severe, Acute Exacerbations of Asthma
SAN DIEGO, May 28, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that it will modify the dosing
Read more →MNOVMediciNova Reports First Quarter 2009 Results
SAN DIEGO, May 15, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the firs
Read more →MNOVMediciNova Reports Final Data from Phase II MN-221 Emergency Department Clinical Trial (MN-221-CL-006); Hospitalization Rates Decrease 45 Percent With MN-221 Plus Standardized Care in Asthma Patients
SAN DIEGO, April 22, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced final results from its Phase
Read more →MNOVShintaro Asako Chief Financial Officer Phone: (858) 373-1500 E-mail: info@medicinova.com Rhonda Chiger Rx Communications Group Phone: (917) 322-2569 E-mail: rchiger@rxir.com FOR IMMEDIATE RELEASE MediciNova Repo
MediciNova Reports Fourth Quarter and Full Year 2008 Results SAN DIEGO, Calif. March 31, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code
Read more →MNOVMediciNova Reports Fourth Quarter and Full Year 2008 Results
SAN DIEGO, March 31, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fo
Read more →MNOVShintaro Asako Chief Financial Officer Phone: 858-373-1500 E-mail: info@medicinova.com FOR IMMEDIATE RELEASE MediciNova Sends Letter to Avigen Board of Directors
CONTACT: Shintaro Asako Chief Financial Officer Phone: 858-373-1500 E-mail: info@medicinova.com MediciNova Sends Letter to Avigen Board of Directors SAN DIEGO, Calif. March 24, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Glo
Read more →MNOVMediciNova Sends Letter to Avigen Board of Directors
SAN DIEGO, March 24, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today sent the following letter to the Board
Read more →MNOVShintaro Asako Chief Financial Officer Phone: 858-373-1500 E-mail: info@medicinova.com FOR IMMEDIATE RELEASE MediciNova Reaffirms Proposal to Acquire Avigen, Inc.
CONTACT: Shintaro Asako Chief Financial Officer Phone: 858-373-1500 E-mail: info@medicinova.com MediciNova Reaffirms Proposal to Acquire Avigen, Inc. SAN DIEGO, Calif. February 9, 2009 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Glob
Read more →MNOVMediciNova Reaffirms Proposal to Acquire Avigen, Inc.
SAN DIEGO, Feb. 9, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today reaffirmed its proposal to acquire Avige
Read more →MNOVMediciNova Reports Interim Phase II Data From MN-221 Emergency Department Study
SAN DIEGO, Jan. 12, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced interim results from two plan
Read more →MNOVMediciNova Proposes to Acquire Avigen, Inc.
SAN DIEGO, Dec. 23, 2008 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it made a proposal to ac
Read more →MNOVMediciNova, Inc. 4350 La Jolla Village Drive, Suite 950 San Diego, CA 92122
4350 La Jolla Village Drive, Suite 950 Zola Horovitz, Ph.D. Chairman of the Board 1301 Harbor Bay Parkway The purpose of this letter is to provide you with more details concerning the recent expression of interest MediciNova, Inc. ( MediciNova ) made to Avigen, Inc. ( Avigen
Read more →MNOVMediciNova Reports Third Quarter 2008 Results
SAN DIEGO, Nov. 10, 2008 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced financial results for the thir
Read more →MNOVMediciNova, Inc. 2008 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform A
New Lesions at Month 2 72 64 56 # Patients w. 1 PBH (% of Pts. w. New Lesions) 41 (56.9%) 33 (51.6%) 28 (50%) Mean Proportion of Lesions Evolving to PBH 0.24 0.20 0.16 Median Proportion of Lesions Evolving to PBH 0.17 0.08 0.04 Relative Risk (for Evolution to PBH) vs. placebo 0.7
Read more →MNOVShintaro Asako Chief Financial Officer Phone: (858) 373-1500 E-mail: info@medicinova.com Rhonda Chiger Rx Communications, LLC Phone: (917) 322-2569 E-mail: rchiger@rxir.com FOR IMMEDIATE RELEASE MediciNova Repor
MediciNova Reports Third Quarter 2008 Results SAN DIEGO, Calif. November 10, 2008 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875
Read more →MNOVMediciNova to Present At the Rodman and Renshaw 10th Annual Healthcare Conference
SAN DIEGO, Nov. 3, 2008 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Shintaro Asako, Chief Fin
Read more →MNOVMediciNova to Present At the 7th Annual BIO Investor Forum
SAN DIEGO, Oct. 22, 2008 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Shintaro Asako, Chief Fin
Read more →MNOVMediciNova Reports Positive Preliminary Results from Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
SAN DIEGO, Sept. 9, 2008 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported positive preliminary results fr
Read more →MNOVMediciNova to Present At Merriman Curhan Ford's 5th Annual Investor Summit 2008
SAN DIEGO, Sept. 8, 2008 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Dr. Michael Kalafer, Chi
Read more →MNOVMediciNova Reports Second Quarter 2008 Results
SAN DIEGO, Aug. 11, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced financial results for the seco
Read more →MNOVMediciNova to Present At the 4th Annual Collins Stewart Growth Conference
SAN DIEGO, July 7, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Dr. Richard Gammans, Chief
Read more →MNOVMediciNova to Host Analyst/Investor Meeting in New York City
SAN DIEGO, July 2, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced it will host an analyst/investo
Read more →MNOVMediciNova Initiates Phase II Clinical Trial of MN-221 in Moderate to Severe Asthma Patients
SAN DIEGO, June 23, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has initiated dosing
Read more →MNOVMediciNova to Present At the Rodman and Renshaw 5th Annual Global Healthcare Conference
SAN DIEGO, May 13, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Shintaro Asako, Chief Fina
Read more →MNOVMediciNova Reports First Quarter 2008 Results
SAN DIEGO, May 12, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the firs
Read more →MNOVMediciNova, Inc. 2008 2 Statements in this presentation that are not historical in nature constitute forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform
USC, Formerly Prof. Pitt; Advisor to JAFCO, Tanabe Director, Avigen, Inc. Richard Gammans, PhD, MBA Richard Gammans , PhD, MBA Gammans , PhD, MBA , PhD, MBA Chief Development Officer 30 Incara, Indevus, BMS Kenneth W. Locke, PhD Kenneth W. Locke, PhD Chief Scientific Officer 23 T
Read more →MNOVMediciNova Reports Clinical Results From Two-Year Phase II Clinical Trial of MN-166 in Multiple Sclerosis
SAN DIEGO, April 7, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced positive clinical findings fro
Read more →MNOVMediciNova to Present Additional Clinical Data Demonstrating Potential Neuroprotection Benefits of MN-166 in Multiple Sclerosis At the 18th Meeting of the European Neurological Society
SAN DIEGO, April 2, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it will present addition
Read more →MNOVMediciNova Initiates Phase II Clinical Trial of MN-221 in Status Asthmaticus Patients
SAN DIEGO, March 31, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced the initiation of a Phase II
Read more →MNOVMediciNova Announces Record Date for Annual Meeting
SAN DIEGO, March 27, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it has scheduled its 2008 Annual Meeting
Read more →MNOVMediciNova Reports Fourth Quarter and Full Year 2007 Results
SAN DIEGO, March 17, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the fo
Read more →MNOVShintaro Asako Chief Financial Officer Phone: 858-373-1500 E-mail: info@medicinova.com Rhonda Chiger Rx Communications, LLC Phone: (917) 322-2569 E-mail: rchiger@rxir.com FOR IMMEDIATE RELEASE MEDICINOVA REPORTS
MEDICINOVA REPORTS CASH, CASH EQUIVALENTS AND SHORT- TERM MARKETABLE SECURITIES AS OF DECEMBER 31, February 8, 2008 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Trading Symbol: MNOV) and the Hercules Market of the Osaka Secu
Read more →MNOVMediciNova Reports Cash, Cash Equivalents and Short-Term Marketable Securities as of December 31, 2007 (Unaudited)
SAN DIEGO, Feb. 8, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that MediciNova had approximat
Read more →MNOVMediciNova's MN-166 Reduces Persistent Black Hole Formation in Multiple Sclerosis Patients
SAN DIEGO, Feb. 1, 2008 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced additional data from a double-
Read more →MNOVMediciNova, Inc. 2008 2 This presentation contains forward looking statements that involve risks and uncertainties. These forward looking statements include, but are not limited to, statements regarding our strategies an
USC, Formerly Prof. Pitt; Advisor to JAFCO, Tanabe Director, Avigen, Inc. Richard Gammans, PhD, MBA Richard Gammans, PhD, MBA Chief Development Officer 30 Incara, Indevus, BMS Kenneth W. Locke, PhD Kenneth W. Locke, PhD Chief Scientific Officer 23 Tanabe Research Laboratories USA
Read more →MNOVMediciNova Reports Third Quarter 2007 Results
SAN DIEGO, Nov. 9, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the thir
Read more →MNOVShintaro Asako Chief Financial Officer MediciNova, Inc. Phone: 858-373-1500 E-mail: info@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces Withdrawal of Common Stock Offering
MediciNova Announces Withdrawal of Common Stock Offering SAN DIEGO, Calif. November 8, 2007 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 48
Read more →MNOVMediciNova Announces Withdrawal of Common Stock Offering
SAN DIEGO, Nov. 8, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it had withdrawn a propos
Read more →MNOVMediciNova Announces Public Offering of Common Stock
SAN DIEGO, Oct. 25, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), announced today that it plans to publicly off
Read more →MNOVMediciNova Reports Phase IIa Clinical Study Results for MN-305, a Treatment for Insomnia
SAN DIEGO, Oct. 18, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced results from a Phase IIa clin
Read more →MNOVMediciNova, Inc. 2007 2 This presentation contains forward looking statements that involve risks and uncertainties. These forward looking statements include, but are not limited to, statements regarding our strategies an
USC, Pitt; Advisor to JAFCO, Tanabe Director, Avigen, Inc. Richard Gammans, PhD, MBA Richard Gammans, PhD, MBA Chief Development Officer 30 Incara, Indevus, BMS Kenneth W. Locke, PhD Kenneth W. Locke, PhD Chief Scientific Officer 23 Tanabe Research Laboratories USA, Indevus, Hoec
Read more →MNOVMediciNova Reports Positive Phase IIa Clinical Study Results for MN-221, a Novel Treatment for Status Asthmaticus
SAN DIEGO, Oct. 9, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced positive results from a Phase
Read more →MNOVMediciNova Will Announce Clinical Results From a Phase IIa Clinical Study for MN-221, a Novel Treatment for Status Asthmaticus, On Tuesday, October 9, 2007 At 3:00 a.m. Eastern Time
SAN DIEGO, Oct. 8, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), will announce results of a Phase IIa clinical
Read more →MNOVMediciNova to Present At the 2007 BIO InvestorForum
SAN DIEGO, Calif., Oct. 4, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Kenneth Locke, PhD
Read more →MNOVMediciNova to Present At the 2007 UBS Global Life Sciences Conference
SAN DIEGO, Sept. 10, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Yuichi Iwaki, M.D., PhD.
Read more →MNOVMediciNova Announces Rule 10b5-1 Stock Purchase Plan
SAN DIEGO, Sept. 11, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Yuichi Iwaki, M.D., Ph.
Read more →MNOVMediciNova Reports Phase Ib Clinical Study Results for MN-221, a Novel Treatment for Preterm Labor
SAN DIEGO, Aug. 17, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced results from its Phase Ib cli
Read more →MNOVMediciNova Reports Second Quarter 2007 Results
SAN DIEGO, Aug. 9, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced financial results for the seco
Read more →MNOVMediciNova to Present Clinical Data On MN-029 At the 14th European Cancer Conference -- ECCO 14
SAN DIEGO, Aug. 7, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it will present findings
Read more →MNOVNon Confidential Presentation July 2007 2 This presentation contains forward looking statements that involve risks and uncertainties. These forward looking statements include, but are not limited to, statements regarding
USC, Pitt; Advisor to JAFCO, Tanabe; Director, Avigen, Inc. Richard Gammans, PhD, MBA Chief Development Officer 30 Incara, Indevus, BMS Kenneth W. Locke, PhD Chief Scientific Officer 23 Tanabe Research Laboratories USA, Indevus, Hoechst Shintaro Asako, CPA Chief Financial Officer
Read more →MNOVMediciNova Announces New Strategic Initiative
SAN DIEGO, June 26, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that based on recent clinical
Read more →MNOVMediciNova, Inc. 2007 This presentation may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include statements regarding the expected progre
MediciNova, Inc. 2007 MediciNova, Inc. Today MediciNova, Inc. Today Market driven, commercially focused mid stage pharma company Innovative business model: Steady inflow of high quality molecules, primarily from mid size Japanese pharma Focus on large, lucrative, underserved mark
Read more →MNOVMediciNova to Present At the J.M. Dutton Health Science Small Cap Conference and the Friedman Billings Ramsey Growth Conference
SAN DIEGO, May 25, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that MediciNova will present a
Read more →MNOVShintaro Asako Chief Financial Officer Phone: 858-373-1500 info@medicinova.com Bonnie Feldman Vice President of Investor Relations Phone: 858-373-1500 bfeldman@medicinova.com FOR IMMEDIATE RELEASE MediciNova Ann
MediciNova Announces First Quarter 2007 Financial Results SAN DIEGO, Calif. May 10, 2007 MediciNova, Inc., a biopharmaceutical company (Nasdaq Global Market: MNOV and Hercules Market, Osaka Securities Exchange Code Number: 4875), today announced financial results for the quarte
Read more →MNOVMediciNova Announces First Quarter 2007 Financial Results
SAN DIEGO, May 10, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company (Nasdaq:MNOV) (Hercules Market of the Osaka Securities Exchange: Code Number: 4875), today announced financial results for the quarter ended March 31, 2007. A detailed discussion of financi
Read more →MNOVMediciNova, Inc.
2:00 PM Pacific Time Operator: Good day, ladies and gentlemen and welcome to MediciNova s conference call discussing certain recently clinical results. At this time all participants are in a listen-only mode. Later we will hold a question and answer session and I will give you
Read more →MNOVKenneth W. Locke, Ph.D. Chief Business Officer E-mail: locke@medicinova.com Bonnie Feldman, D.D.S., M.B.A. Vice President of Investor Relations E-mail: BFeldman@medicinova.com FOR IMMEDIATE RELEASE MediciNova An
MediciNova Announces Positive Clinical Results from MN-166 Phase II Multiple Sclerosis Trial Conference Call to Discuss Results on Thursday, March 29, 2007, at 2:00 p.m. Pacific Time SAN DIEGO, Calif. March 27, 2007 MediciNova, Inc., a biopharmaceutical company that is publicl
Read more →MNOVMediciNova Announces Positive Clinical Results From MN-166 Phase II Multiple Sclerosis Trial
SAN DIEGO, March 27, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced positive clinical findings fr
Read more →MNOVMediciNova to Present At the Lehman Brothers Tenth Annual Global Healthcare Conference
SAN DIEGO, March 14, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., (Nasdaq:MNOV) (Hercules Market of the Osaka Securities Exchange: Code Number: 4875), a biopharmaceutical company focused on accelerated global development and commercialization of innovative pharmaceutical products,
Read more →MNOVMediciNova to Present Phase II Clinical Trial Results for MN-001, a Novel Oral Treatment for Bronchial Asthma, at the 2007 AAAAI Annual Meeting
SAN DIEGO, Feb. 21, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc. (Nasdaq:MNOV) (Hercules Market of the Osaka Securities Exchange: Code Number: 4875), a biopharmaceutical company focused on accelerating the global development and commercialization of innovative pharmaceutical product
Read more →MNOVMediciNova Reports 2006 Financial Results
SAN DIEGO, Feb. 15, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc. (Nasdaq:MNOV) (Hercules Market of the Osaka Securities Exchange: Code Number: 4875), a biopharmaceutical company focused on accelerating the global development and commercialization of innovative pharmaceutical product
Read more →MNOVMediciNova to Host Year End Call On February 15, 2007
SAN DIEGO, Feb. 6, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that it will report its year end 2006 financial results
Read more →MNOVBonnie Feldman Vice President of Investor Relations MediciNova, Inc. Phone: 858-373-8000 E-mail: BFeldman@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces Pricing of Common Stock Offering
MediciNova Announces Pricing of Common Stock Offering SAN DIEGO, Calif. January 29, 2007 MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today an
Read more →MNOVMediciNova Announces Pricing of Common Stock Offering
SAN DIEGO, Jan. 29, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the pricing of a public offering of 1,000,000 s
Read more →MNOVMediciNova Initiates Phase II Clinical Trial for MN-305, a Novel Treatment for Insomnia
SAN DIEGO, Jan. 22, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the initiation of a Phase II clinical study to
Read more →MNOVMediciNova Announces Results From a Phase II/III Interstitial Cystitis Trial With MN-001
SAN DIEGO, Jan. 16, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (Trading Symbol: MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the results from its Phase II/III rand
Read more →MNOVMediciNova Establishes Japanese Subsidiary in Tokyo
SAN DIEGO, Jan. 4, 2007 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced the establishment of MediciNov
Read more →MNOVMediciNova Announces Initiation of Phase II Clinical Program For MN-221, a Novel Treatment For Status Asthmaticus
SAN DIEGO, Dec. 18, 2006 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on NASDAQ (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the initiation of the Phase II clinical program
Read more →MNOVMediciNova Establishes a European Subsidiary in the U.K.
SAN DIEGO, Dec. 13, 2006 (PRIME NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced the establishment of MediciNo
Read more →MNOVMediciNova, Inc. (MNOV) Chairman and Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell
ADVISORY, Dec. 6, 2006 (PRIME NEWSWIRE) -- Yuichi Iwaki, Chairman and Chief Executive Officer will preside over NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio Thursday, December 7, 2006 at 4 p.m. ET Johnson@medicinova.com Jolene Libretto; 646.441.522
Read more →MNOVShintaro Asako Vice President and CFO MediciNova, Inc. Phone: 858-373-1500 E-mail : info@medicinova.com FOR IMMEDIATE RELEASE MediciNova Appoints Shintaro Asako as Chief Financial Officer
MediciNova Appoints Shintaro Asako as Chief Financial Officer SAN DIEGO, Calif. November 9, 2006 MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the appointment of
Read more →MNOVKenneth W. Locke, Ph.D. Chief Business Officer MediciNova, Inc. Phone: 858-373-1200 E-mail: locke@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from
MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from Meiji Seika Kaisha, New Mechanisms of Action Against Blood Clot Formation Demonstrated in Preclinical Studies SAN DIEGO, Calif. October 31, 2006 MediciNova, Inc., a biopharmaceutical company that is
Read more →MNOVShintaro Asako MediciNova, Inc. Phone: 858-373-1500 E-mail : asako@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces Shareholder Approval of One-for-Ten Reverse Stock Split of Outstanding Common Stock
MediciNova Announces Shareholder Approval of One-for-Ten Reverse Stock Split of Outstanding Common SAN DIEGO, Calif. October 15, 2006 MediciNova, Inc., a development-stage biopharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange
Read more →MNOVShintaro Asako MediciNova, Inc. Phone: 858-373-1500 E-mail: asako@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces Extension of Share Repurchase Program
MediciNova Announces Extension of Share Repurchase Program SAN DIEGO, Calif. June 14, 2006 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced that the Board of
Read more →MNOVKenneth W. Locke, Ph.D. Chief Business Officer MediciNova, Inc. Phone: 858-373-1200 E-mail: locke@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces the Initiation of a Clinical Development Program to Eva
MediciNova Announces the Initiation of a Clinical Development Program to Evaluate MN-221 for the Treatment of Status Asthmaticus SAN DIEGO, Calif. June 13, 2006 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Se
Read more →MNOVKenneth W. Locke, Ph.D. Chief Business Officer MediciNova, Inc. Phone: 858-373-1200 E-mail: locke@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces Results from a Phase II/III Generalized Anxiety Disorde
MediciNova Announces Results from a Phase II/III Generalized Anxiety Disorder Trial with MN-305 June 11, 2006 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced
Read more →MNOVKenneth W. Locke, Ph.D. Chief Business Officer MediciNova, Inc. Phone: 858-373-1200 E-mail: locke@medicinova.com FOR IMMEDIATE RELEASE MediciNova Presents MN-029 Phase I Safety and Tumor Blood Flow Reduction Res
MediciNova Presents MN-029 Phase I Safety and Tumor Blood Flow Reduction Results in Cancer Patients at ASCO Annual Meeting SAN DIEGO, Calif. June 4, 2006 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securitie
Read more →MNOVShintaro Asako MediciNova, Inc. Phone: 858-373-1500 E-mail : asako@medicinova.com FOR IMMEDIATE RELEASE MediciNova, Inc. Appoints Arlene M. Morris and Alan W. Dunton To Its Board of Directors
MediciNova, Inc. Appoints Arlene M. Morris and Alan W. Dunton To Its Board of Directors SAN DIEGO, Calif. May 11, 2006 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), toda
Read more →MNOVShintaro Asako MediciNova, Inc. Phone: 858-373-1500 E-mail: asako@medicinova.com FOR IMMEDIATE RELEASE MediciNova, Inc. Appoints Jeff Himawan To Its Board of Directors
MediciNova, Inc. Appoints Jeff Himawan To Its Board of Directors SAN DIEGO, Calif. January 12, 2006 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced the app
Read more →MNOVKenneth W. Locke, Ph.D. Chief Business Officer MediciNova, Inc. Phone: 858-373-1200 E-mail : locke@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces Positive Clinical Results with MN-001 in a Phase II As
MediciNova Announces Positive Clinical Results with in a Phase II Asthma Trial SAN DIEGO, Calif. December 13, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today an
Read more →MNOVShintaro Asako MediciNova, Inc. Phone: 858-373-1500 E-mail: asako@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces Share Repurchase Program
MediciNova Announces Share Repurchase Program SAN DIEGO, Calif. December 5, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced that the Board of Directors
Read more →MNOVShintaro Asako MediciNova, Inc. Phone: 858-373-1500 Email: asako@medicinova.com FOR IMMEDIATE RELEASE MediciNova announces departure of Executive Officers
MediciNova announces departure of Executive Officers SAN DIEGO, Calif. September 30, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced that the Board of
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE SEC Declares MediciNova s Registration Statement on Form S-1 Effective
SEC Declares MediciNova s Registration Statement on September 21, 2005 MediciNova, Inc. announced today that it s registration statement on Form S-1 filed with the Securities and Exchange Commission on September 19, 2005 was declared effective on September 21, 2005. Pursuant to
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces the Completion of Enrollment of a Phase II Study for its Novel, Oral Asthma Treatmen
MediciNova Announces the Completion of Enrollment of a Phase II Study for Novel, Oral Asthma Treatment Data Expected to be Available by the end of 2005 SAN DIEGO, Calif. September 7, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Herc
Read more →MNOVFinancial Statements For the Six Months Ended
Financial Statements For the Six Months Ended June 30, 2005 August 15, 2005 Name of Listed Company: MEDICINOVA, INC. Listed Exchanges: Hercules, Osaka Ex. Code Number: 4875 Location of Head Office: California, U.S.A. (URL http://www.medicinova.com ) Representative Officer:
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova Initiates a Phase II Clinical Trial with MN-166 in Multiple Sclerosis Novel oral compound demo
MediciNova Initiates a Phase II Clinical Trial with MN-166 in Multiple Sclerosis demonstrated benefits in earlier clinical studies in patients with relapsing-remitting MS SAN DIEGO, Calif. August 2, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly tra
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova Provides Mid-Year Review of the Company s Clinical Programs
MediciNova Provides Mid-Year Review of the SAN DIEGO, Calif. July 25, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today provided a mid-year status report on its cl
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova Initiates a Second Phase I Clinical Trial with MN-029 in Cancer Patients Novel Vascular Target
MediciNova Initiates a Second Phase I Clinical Trial with MN-029 in Cancer Patients Novel Vascular Targeting Agent Well Tolerated in Earlier Trial SAN DIEGO, Calif. June 17, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Mar
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova Initiates a Phase II Clinical Trial with MN-001 in Interstitial Cystitis
MediciNova Initiates a Phase II Clinical Trial with MN-001 in Interstitial Cystitis SAN DIEGO, Calif. May 24, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today an
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson @ medicinova.com FOR IMMEDIATE RELEASE MediciNova Initiates a Phase II Clinical Trial with MN-001 in Asthma Oral Agent is Characterized as Pot
MediciNova Initiates a Phase II Clinical Trial with Oral Agent is Characterized as Potentially Broadly Effective SAN DIEGO, Calif. March 28, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchan
Read more →MNOVFinancial Statements For the Year Ended
Financial Statements For the Year Ended December 31, 2004 March 22, 2005 Name of Listed Company: MEDICINOVA, INC. Listed Exchanges: Hercules, Osaka Ex. Code Number: 4875 Location of Head Office: California, U.S.A. (URL http://www.medicinova.com) Representative Officer: Tak
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova to Present at the Lehman Brothers 8 th Annual Global Healthcare Conference
MediciNova to Present at the Lehman Brothers 8th Annual Global Healthcare Conference March 22, 2005 MediciNova, Inc., (Code number: 4875, OSE Hercules Market) a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange, tod
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova Initiates a Phase I Clinical Trial with MN-221 a New Agent for the Management of Preterm Labor
MediciNova Initiates a Phase I Clinical Trial with MN-221 a New Agent for the Management of Preterm Labor SAN DIEGO, Calif. March 14, 2005 MediciNova, Inc., (Code number: 4875, OSE Hercules Market) a specialty pharmaceutical company that is publicly traded on the Hercules Mar
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova sets Date and Conference for Full Year 2004 Earnings Announcement
MediciNova sets Date and Conference for Full Year 2004 SAN DIEGO, Calif. - March 10, 2005 MediciNova, Inc. (Code Number: 4875, Hercules OSE) will announce its financial results for the fiscal year of 2004 on Tuesday, March 22, 2005. MediciNova will also hold a conference in Tok
Read more →MNOVBrian Anderson MediciNova, Inc. Phone: 858-622-9752 Email: banderson@medicinova.com FOR IMMEDIATE RELEASE MediciNova Announces Exercise of Underwriter s Over-allotment Option
MediciNova Announces Exercise of Underwriter s Over-allotment Option SAN DIEGO, Calif. March 8, 2005 MediciNova, Inc., (Code number: 4875, OSE Hercules Market) a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange, t
Read more →MNOVMediciNova Announces the Start of a Phase II Clinical Trial with Novel Anti-Anxiety Agent Specialty Pharmaceutical Company Embarks on Ambitious Clinical Program
MediciNova Announces the Start of a Phase II Clinical Trial with Novel Anti-Anxiety Agent Specialty Pharmaceutical Company Embarks on Ambitious Clinical Program SAN DIEGO, Calif. March 1, 2005 MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the
Read more →MNOVMEDICINOVA, INC., CLOSES INITIAL PUBLIC OFFERING San Diego
MEDICINOVA, INC., CLOSES INITIAL PUBLIC OFFERING San Diego, February 8, 2005 MediciNova, Inc. announced today that it has closed its initial public offering of 30,000,000 shares of its common stock, at a price of 400, or approximately $3.88, per share. The initial public offeri
Read more →Competitive Position
How MNOV ranks across every disease it competes inCompetitive Position is a premium feature
See how MNOV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial